Characterization of Pharmaceutical Materials by Thermal and Analytical Methods by Maheswaram, Manik Pavan Kumar
Cleveland State University
EngagedScholarship@CSU
ETD Archive
2012
Characterization of Pharmaceutical Materials by
Thermal and Analytical Methods
Manik Pavan Kumar Maheswaram
Cleveland State University
Follow this and additional works at: https://engagedscholarship.csuohio.edu/etdarchive
Part of the Chemistry Commons
How does access to this work benefit you? Let us know!
This Dissertation is brought to you for free and open access by EngagedScholarship@CSU. It has been accepted for inclusion in ETD Archive by an
authorized administrator of EngagedScholarship@CSU. For more information, please contact library.es@csuohio.edu.
Recommended Citation
Maheswaram, Manik Pavan Kumar, "Characterization of Pharmaceutical Materials by Thermal and Analytical Methods" (2012). ETD
Archive. 190.
https://engagedscholarship.csuohio.edu/etdarchive/190
CHARACTERIZATION OF PHARMACEUTICAL MATERIALS  
BY THERMAL AND ANALYTICAL METHODS 
 
 
 
 
MANIK PAVAN KUMAR MAHESWARAM 
 
 
 
 
 
 
Master of Science in Chemistry 
Cleveland State University  
May 2012 
 
 
Submitted in partial fulfillment of requirements for the degree of  
DOCTOR OF PHILOSOPHY IN BIOANALYTICAL CHEMISTRY 
at the  
CLEVELAND STATE UNIVERSITY 
May, 2012 
This thesis has been approved for the  
Department of Chemistry and the  
College of Graduate Studies by 
 
________________________________Date: __________ 
Dr. Alan Riga, Department of Chemistry, Cleveland State University 
Primary Research Advisor 
 
 
______________________________Date: __________ 
 Dr. Mekki Bayachou, Department of Chemistry, Cleveland State University 
Dissertation Committee Chairperson 
 
 
______________________________Date: __________ 
Dr. John Turner, Department of Chemistry, Cleveland State University 
Advisory Committee Member 
 
 
_____________________________Date: __________ 
Dr. Bin Su, Department of Chemistry, Cleveland State University 
Advisory Committee Member 
 
 
______________________________Date: __________ 
Dr. Tobili Sam-Yellowe, Department of BGES, Cleveland State University 
External Advisory Committee Member 
DEDICATION 
This thesis dissertation is dedicated to my parents M. Rukmaiah, M. Sujatha, 
and my brothers M. Manik Prabhu and M. Manik Pradeep Kumar; my sister-in-law             
M. Swetha and my nephew M. Sathvik; my loving friends for their endless love, support 
and encouragement they provided me throughout the years. 
Also, this thesis is dedicated to my “Guru”- Dr. Alan Riga for his outstanding 
pedagogy. 
 
 
  
ACKNOWLEDGEMENTS 
First and foremost, I would like to express my deep and sincere gratitude to Dr. 
Alan T. Riga, my advisor, for his valuable advice, immense support and encouragement 
in the journey of my academic and scientific research. I wish to thank him for introducing 
me to the field of Thermal Analysis. Dr. Alan Riga was very patient helpful and has 
always been there when I needed some encouragement with my work or just as a friend 
to talk to. There is so much that I have learned from him during the years that we have 
worked together. Writing this thesis would not have been possible without his interest 
and guidance.  
This thesis was carried out in the Department of Chemistry, Cleveland State 
University Cleveland, Ohio. Part of the work was done in the College of Pharmacy 
Practice, University of Toledo, Ohio and The Department of Macromolecular Science 
and Engineering, Case Western Reserve University, Cleveland, Ohio. 
I would like to thank all the people who have been involved in this research, 
during the years 2008 – 2012. 
 I am especially thankful to Dr. Kenneth. S. Alexander for his positive attitude 
and kind support with my work. I also express my gratitude for giving me the opportunity 
to use the facilities at The College of Pharmacy Practice, University of Toledo, OH and 
his friendly advice during the years. 
Secondly, I would further like to thank Dr. Mekki Bayachou, Dr. John Turner, Dr. 
Bin Su and Dr. Tobili-Sam-Yellowe for their invaluable time and support and for being 
part of my dissertation committee.  
Finally, I would like to thank Dr. Indika Perera for his advice, immense support 
and encouragement during the completion of my doctoral studies. Without him Riga 
Research Team is incomplete.  
I would like to bestow this thesis in particular to my family and friends and my 
Riga Research team members especially Indika, M. Ellen Matthews, Hareesha, 
Dhruthiman, Shravan, Lakshmi, Jeff Fruscella, and Rajgopal. I thank Robert Cannon for 
helping me out with PXRD studies. 
To all my friends, thank you for your understanding and encouragement in my 
many, many moments of crisis. Your friendship makes my life a wonderful experience. I 
cannot list all the names here, but you are always on my mind. 
Thank you, God, for always being there for me.  
vi 
CHARACTERIZATION OF PHARMACEUTICAL MATERIALS BY 
THERMAL AND ANALYTICAL METHODS 
MANIK PAVAN KUMAR MAHESWARAM 
ABSTRACT 
            Morphological and thermodynamic transitions in drugs as well as their amorphous 
and crystalline content in the solid state have been distinguished by Thermal Analytical 
techniques, which include dielectric analysis (DEA), differential scanning calorimetry 
(DSC), and macro-photo-micrography. These techniques were used to establish a 
structure vs. property relationship with the United States Pharmacopeia (USP) standard 
set of active pharmaceutical ingredients (API). DEA measures and differentiates the 
crystalline solid (low; 10-2 pS cm-1) and amorphous liquid (high; 106 pS cm-1) API 
electrical ionic conductivity. DEA ionic conductivity cycle establishes the quantitative 
amorphous/ crystalline content in the solid state at frequencies of 0.1 - 1.00 Hz and to 
greater than 30o C below the melting transition as the peak melting temperature. This 
describes the “activation energy method”. An Arrhenius plot, log ionic conductivity vs. 
reciprocal temperature (K-1), of the pre-melt DEA transition yields frequency dependent 
activation energy (Ea, J mol-1) for the complex charging in the solid state. The amorphous 
content is inversely proportional to the Ea. Where, Ea for the crystalline form is higher 
and lower for the amorphous form with a standard deviation of ± 2%. An alternate 
technique has been established for the drugs of interest based on an obvious amorphous 
and crystalline state identified by macro-photomicrography and compared to the 
conductivity variations. This second “empirical method” correlates well with the 
“activation energy” method. A comparison of overall average amorphous content by the 
vii 
empirical method had a linear relationship with the activation energy method with a 
correlation coefficient of R2 = 0.925.  
          Additionally, new test protocols have been developed which describe the 
temperature and material characterization calibration of thermal analyzers with 
pharmaceuticals. These test protocols can be blended into a universal standard protocol 
for DSC, DEA and thermomechanical analysis (TMA). While calibrating DSC, a 
thermodynamic transition i.e. a change in heat flow, is marked by absorption (or release) 
of energy by the calibrants; for DEA, at the melt transition temperature, an abrupt change 
in DEA permittivity is observed; for TMA, at the transition temperature of the test 
specimen, there is a change in dimensional stability and a measured change in the 
coefficient of thermal expansion or contraction/softening is recorded. These test protocols 
were accomplished based on “The ASTM standard test methods for temperature 
calibration of thermal analytical methods”. The R2 correlation value of the calibrants for 
known standard literature transition temperatures vs. DSC melting peak temperatures, 
DEA Permittivity melting temperatures and TMA extrapolated onset-melting 
temperatures was 0.999. 
          Next, drug salts were investigated by DEA in order to evaluate ionic conductivity 
in pharmaceuticals. The ionic conductivity varied by several orders of magnitude in the 
amorphous form of the drug salt. The drug salts have an enhanced DEA ionic 
conductivity due to their ionic mobility of the salt component in the liquid phase. The 
primary aim of this study is to investigate the thermal and electrical behavior of 
pharmaceutical hydrochlorides using DEA and DSC techniques. From these analyses we 
can predict the quality, stability and behavior of a drug salt. This study also provides a 
viii 
comprehensive characterization of ionic conductivity and molecular mobility (related to 
tan delta in DEA) properties in pharmaceutical salts through the measurement of the 
characteristic activation energies Ea (k) and Ea (τ) as well as polarization times (τ). The 
typical ionic conductivity of a melted drug, i.e. the amorphous phase, is 105 pS cm-1and 
for the salt it is higher than 106 pS cm-1. It is our opinion that a quality and a stable drug 
salt form will have a high ionic conductivity of >105 pS cm-1. The DEA properties 
described here can be further developed to estimate the storage stability or shelf life of 
the drug salts by activation energies and polarization times. Salts with advantageous 
properties are typically patentable as new chemical entities. Electro synthesis is suggested 
for future drug development with the high ionic conductivity of the salts, >105 pS cm-1 to 
aid reaction kinetics to form new complexes or modified salts.  
          The dielectric science developed to understand the crystalline and amorphous 
components in pharmaceuticals would be validated by calorimetry, X-ray diffraction and 
scanning electron microscopy. It has been established that the crystalline and amorphous 
content measured by the DEA activation energy method is related to the DSC melting, 
glass-transition profile as well as the crystal structure by X-ray diffraction and scanning 
electron microscopic images.  
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OBJECTIVES 
  The main objective of this thesis was to characterize the selected model drugs as 
APIs using Differential Scanning Calorimetry (DSC) and Dielectric Analysis (DEA). 
Then develop a structure versus property relationship. The latter process guided the 
research to acquire a novel and efficient thermal analytical method for accurate and 
precise quantification of crystalline and amorphous content in pharmaceutical solids 
using a combined DSC and DEA Method. The electrical properties of the drugs and 
nylon 6 polymers were studied using Dielectric Analysis. The physical properties of the 
pharmaceutical solids were studied by employing DSC and TMA. Employing Scanning 
Electron Microscopy (SEM), Powder X-ray diffraction (PXRD), and Macro-
photomicrography the structural attributes of the solids (drugs) were studied.  The initial 
phase of this thesis was to characterize and develop new unique calibration procedures 
for the pharmaceutical industry based on physical properties of pure APIs and Excipients. 
This study describes the temperature and material characterization calibration of 
differential scanning calorimeters, dielectric analyzers and thermomechanical analyzer 
with pharmaceuticals over the temperature range of 25o C to 250o C. The theory of 
dielectric behavior of complex chemicals, pharmaceuticals, and polymers was also 
studied based on the multiple relaxation times, Cole-Cole plot of a Debye curve (for 
single relaxation time) and The Polaron theory or the “hopping model for conduction” 
and many alternative theories. These theories are used to describe the transfer of charge 
between various specific localized sites within a material under the influence of an 
electric field. This research was under taken as the basis for the later part of this study, 
where the drugs and an excipient were carefully evaluated by these techniques (DEA, 
xxix 
DSC and TMA) and the data interpreted was compared and ranked. Excipients are the 
inactive pharmaceuticals that are used to make up a medication. The DEA technique is a 
relative newcomer to thermal analysis in pharmaceutical field and it added a significant 
amount of new characterization data. DEA uniquely measures the electrical properties of 
the organic chemicals, drugs and excipients; polymers studied and revealed new physical-
chemical properties, e.g., example, electrical ionic conductivity is a function of 
temperature and time.  
  In the next phase of my study, pharmaceutical solids (drugs) and nylon 6 
polymers were characterized and evaluated further for morphological and thermodynamic 
transitions by the DSC and DEA instrumental methods. Nylon 6 polymers were used as 
models (reference polymers) for crystalline and amorphous content. These techniques 
were used successfully to establish a structure vs. property relationship with the API of 
drugs. The physical and electrical properties of the drugs were determined and were used 
to identify and quantify the crystalline and amorphous content in pharmaceutical solids. 
The major value of this research is to develop a novel analytical protocol utilizing 
dielectric analysis to define and quantify the crystalline and amorphous content in 
pharmaceutical solids. These inventive techniques will give pharmaceutical scientists 
new insights in how to understand the nature and behavior of the drug in the solid state as 
this information is of the utmost importance in pre-formulation studies of drug 
development.  
  Next, I studied the thermal and electrical behavior of hydrochloride salts of drug 
substances using thermo-analytical methods. This analysis provides a perspective on the 
use of the data from these techniques for predicting the quality, stability and behavior of 
xxx 
these materials. This study is also aimed at providing a comprehensive characterization of 
ionic conductivity and molecular mobility, related to tan delta as the                              
(loss factor/ permittivity) in DEA, properties in pharmaceutical salts i.e., crystalline and 
amorphous forms through the measurement of the characteristic activation energies        
Ea (k) and Ea (τ) as well as polarization times (τ). 
Finally, this portion of the thesis is to validate the DEA characteristic properties 
of an amorphous and crystalline material by: DSC, SEM, Macro-photography and PXRD. 
Quinapril.HCl (Q.HCl) and Clopidogrel Hydrogen Sulfate (CHS) were selected and 
prepared as model samples for amorphous characterization. These materials were 
prepared by the solvent evaporation method. The DEA confirmation for Q.HCl and CHS 
is based on an overlay of their DEA amorphous form 2nd run to another amorphous 
sample prepared outside by the solvent evaporation method. The overlay was perfect in 
the physical layout of both since they both attained the same ionic conductivity level.  
Additionally, another amorphous entity (quench cooled) compared favorably with the 
DEA amorphous form. 
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CHAPTER I 
INTRODUCTION 
The chemical structure of a drug in a solution and its interaction with its receptor 
determines its activity in the patient [1]. However, in order to deliver the active drug 
molecule and excipients to the body in a physically stable state, i.e. typically as an oral 
solid dosage form, it is necessary to formulate it as a drug product. Therefore, the 
efficacy and safety of a drug product largely depends on the solid-state properties that 
include physicochemical and material properties.  
1.1 Solid Forms 
Presently majority of the solid drugs and dosage forms are prepared from 
crystalline active pharmaceutical ingredients (APIs). Solid materials can exist as either 
crystalline or amorphous forms. The crystalline form is characterized by a regular 
ordered crystal lattice structure, where there is no long-range order in amorphous form, as 
in liquids [2]. Between amorphous and crystalline forms there can be states of partial 
order, as in liquid crystals (see Figure 1.1.). 
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Figure 1.1. Schematic representation of structure of a crystalline and amorphous solid [3] 
Mostly, organic molecules prefer to exist in crystalline solid form. Crystalline 
material is thermodynamically more stable than isolable amorphous material [2]. The 
practical significance of this amorphous property is that there is energetic pressure for an 
amorphous solid to recrystallize, so while selecting an amorphous form of a drug for 
development must be made with this in mind. 
In addition, to variations in the relative amount of molecular order in solids, there 
can also be variations in the nature of the order. The classification of an organic 
molecular solid and its sub classification of crystalline solid are shown in (Figure 1.2.). 
The crystalline solids are divided in to polymorphs and hydrates. Different polymorphs 
have the same molecular structure but the molecules are arranged differently in the 
crystal lattice. The crystal lattice structures of solvates, hydrates and co-crystals are 
similar and are made up of more than one type of molecule. A crystal is composed of the 
API and a guest molecule in the pharmaceutical environment; solvates contain a solvent 
molecule, under ambient conditions organic compounds incorporate water or solvents 
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into their crystal lattice and in co-crystals the guest molecule included in the crystal 
structure [2, 4].  
 
Figure 1.2. The classification of an organic molecular solid 
The solid-state forms have different physicochemical as well as mechanical 
properties. They are as follows: Packing properties (density, refractive index, 
conductivity, hygroscopicity); Thermodynamic properties (Melting/Tg, enthalpy, 
entropy, heat capacity, thermodynamic activity, solubility); spectroscopic properties 
(Electronic, vibrational, rotational and nuclear spin); Kinetic properties (Dissolution rate, 
physical and chemical stability; Surface properties (Surface energy, habit); Mechanical 
properties (Hardness, tensile strength, compressibility, flow ability [5].  
1.1.1 Amorphous state.  During recent years the pharmaceutical scientists have 
studied the amorphous state in detail and there are a few drug products that have reached 
the market [6].  There is a growing interest in the amorphous state in the field of 
TRD - Your Partner for Technical R&D
Background - Definitions
Solid-States 
Organic Molecular Solid
Amorphous Crystalline
Polymorphs Solvates/Hydrates
Monotropic Enantiotropic Reversible Non-reversible  
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pharmaceutics. For example, asthma medicine Accolate® (Zafirlukast) [7, 8]; antibiotic 
Zinnat ® / Ceftin® (cefuroxime axetil) [9, 10], and ACE-inhibitor Accupro® / Accupril® 
(Quinapril.HCl) [11, 12].  However, amorphous solids have poor stability, because of its 
high chemical reactivity, both during manufacturing and storage often hinders the 
development of amorphous drug formulations.  
The significance of amorphous solids in pharmaceutical environment lies in their 
useful properties, instability and common occurrence relative to corresponding crystals. 
Due to the existence of polymorphism in the crystalline state, many scientists have raised 
the question of occurrence of different solid-state forms in the amorphous state. This 
phenomenon is called Polymorphism. A first order phase transition has to separate two 
amorphous phases in order for the polymorphism to exist [13-16]. Polymorphism was 
first found to exist in water and in some inorganic materials [17, 18]. There are some 
evidences that small organic materials also exist as polymorphs [13-16]. 
Based on the molecular packing, intermolecular bonding network, or amorphous material 
having local domains of different densities several theoretical models of amorphous 
materials have been proposed in the literature during recent years [19]. The potential 
energy differs in these regions with different packing densities. The physical and 
chemical properties are significantly affected by these differences in local structure of an 
amorphous material [19]. The heterogeneity nature of the amorphous state combined with 
structural relaxation could explain some of the differences in the differently prepared 
amorphous samples of the same drug or API. 
1.1.1.1 Preparation of amorphous form.  Amorphous material can be prepared 
during several pharmaceutical-processing steps both unintentionally as well as 
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intentionally through different pathways (see Figure 1.3.), through a solution, a liquid, a 
vapor, and a solid state [3, 4, 20].  
 
Figure 1.3. Different pathways to prepare amorphous pharmaceutical materials [21] 
1.1.1.2 Quantification of amorphous content. The determination of amorphous 
content or crystalline content is based on the various differences in the physical 
properties between solids-state forms. There are several methods to quantify crystalline 
and amorphous content in pharmaceutical solids (See Figure 1.4.). 
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Figure 2. Different pathways to prepare amorphous materials.
Amorphous materials are prepared through a solution state by spray or freeze drying as
well as by salting-out or antisolvent addition methods, where the formation of amorphous
material is based on rapid precipitation [3, 38]. In spray drying, solution is sprayed into hot
air and the solvent is evaporated so fast that the molecules remain unorganized. In freeze
drying the solution is rapidly frozen and the solvent is sublimed in low temperature and
pressure. As the solv t is removed the solute molecules remain in the unordered structure
they were frozen in. The same phenomenon is also involved in preparation of amorphous
material through vapour state, if the condensation of the material from vapour state to solid
state occurs fast enough, the molecules remain unorganized.
The fourth pathway to prepare amorphous material is through mechanical activation.
The process varies from the two previous methods. In solid-state transition, the amorphous
state is formed through the disruption of the crystal lattice for example during milling and
dehydration [53]. The amorphous solid is formed, when the amount of crystal defects
accumulates gradually above a critical level. Therefore, the amorphous form is more likely to
possess some qmemoryr of the long-range order of the original polymorph and to have some
seeds or nuclei of the original polymorph left [50, 54, 55]. Cryogrinding of piroxicam forms I
and II led to X-ray amorphous materials that had similar short-range orders but differed in
the residual long-range order [54]. This qmemoryr of the original polymorph can have an
influence on the stability as well as dissolution behaviour of the amorphous sample. This was
observed, when amorphous indomethacin (IMC) was prepared by cryogrinding from both Į-
and Ȗ-IMC [55, 56].
2.4 Process induced changes in amorphicity or crystallinity
In addition to the methods used to deliberately prepare amorphous materials, amorphous
material is often created unintentionally during several pharmaceutical processes, such as
milling, compression and drying (Fig. 3) [38, 57, 58]. However, the change in crystallinity can
Amorphous solid
Transition through
liquid state
− Cooling a melt
Transition through
solid state
− Grinding
− Compression
− Dehydration
Crystalline solid
Transition through
solution state
− Spray drying
− Freeze drying
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Transition through
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Figure 1.4. Comprehensive Characterization of Various Quantification Techniques [22] 
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CHAPTER II 
INSTRUMENTS AND METHODS 
Thermal analysis is the term used to describe the analytical techniques that 
measure the physical and chemical properties of the sample as function of temperature or 
time. Some of the most important thermal analysis includes Differential Thermal 
Analysis (DTA), Differential Scanning Calorimetry (DSC), Thermogravimetry (TG), 
Thermomechanical Analysis (TMA), Dynamic Mechanical Thermal Analysis (DMA), 
and Dielectric Thermal Analysis (DEA). 
2.1 Theory of Dielectric Analysis (DEA) Operation 
2.1.1 Instrument. The DEA technique is relative newcomer to the thermal 
analysis field. It can be used to determine the dielectric properties of a material i.e., 
mobility of an ions and dipoles of a material as a function of time, temperature, and 
frequency. Dielectric instrument   (Figure 2.1. Dielectric Analyzer TA 2970) measures 
two fundamental electrical characteristics of a material.  
• Capacitive (insulating) nature, which represents its ability to store electric 
charge 
• Conductive nature, which represents its ability to transfer electric charge
10 
These electrical properties are important in themselves but have even more 
significance when they are correlated to activity on a molecular level [1-3]. This 
correlation allows you to probe the physical and chemical structure, process behavior, 
and molecular mobility (relaxations) of pharmaceutical materials, chemicals, polymers 
and composites [3-5]. 
 
Figure 2.1. Dielectric Analyzer TA 2970 Instrument 
 
Some uses of dielectric analysis are as follows:  
• Surface properties versus bulk properties 
• Frequency dependence of thermal transitions 
• Frequency-dependent transitions at a constant temperature 
• Influence of Crystallinity or amorphicity  
• Activation energies for transitions 
• Storage stability information 
• Identification of multiple phases 
• Change in properties due to exposure to a given environment (oxidation, 
thermal breakdown) [3,4] 
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2.1.2 Principle.  In dielectric analysis, a sample is placed on a single surface gold 
ceramic inter-digitated electrode (see Figure 2.2.) when an alternating (sinusoidal 
voltage) electric field is applied.  This voltage polarizes the sample, causing an oscillation 
of the molecules at the same frequency as the electric field but has a phase angle (or 
phase shift) δ. This phase angle shift is measured by comparing the applied voltage to the 
measured current (see Figure 2.3.) [4, 5]. The measured induced current is separated into 
capacitive (ε") and conductive (ε!) components via the relationships shown in (Figure 
2.4.). The ratio of ε!/ε" is known as the loss tangent (tanδ).  
Capacitance (C) and conductance (1/R) are calculated using the following equations: 
C (farads) = !!"#$%&"'!!""#$%&  x !"#!!!!"                                                                                               (1) 
1/R (mhos) = !!"#$%&"'!!""#$%&  x cos δ                                                                                           (2) 
Where: 
R = resistance (ohms) 
I = measured current (amps). V = applied voltage (volts) 
f = applied frequency (Hz) ! = Phase angle shift ! = Angular frequency, 2!"(rad/sec) [4, 5] 
 
Figure 2.2. Single surface gold ceramic 
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Figure 2.3. Applied Voltage/ Current Response 
 
 
 
Figure 2.4. Calculations of Capacitive and Conductive Components 
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The current can be measured by using the current to charge a load capacitor and then 
measure the voltage across the capacitor [4, 5].  
Measurements of capacitance and conductance of material are used to calculate 
the following variables over wide range of frequencies, which provide valuable 
information about molecular motion [5, 6]: 
• Permittivity (ε", real part), which is proportional to capacitance and 
measures the alignment of dipoles (molecular groups) in the electric field. 
• Loss factor (ε!, imaginary part) is proportional to conductance or ion 
conductivity and represents the energy required aligning dipoles and 
moving molecular groups or ions. 
• Complex dielectric constant (ε*) consists of both the “real” (permittivity) 
and the “imaginary” (loss factor) parts: ε* = ε"- iε! 
A chemical bond that has an unbalanced distribution of charge in a molecule is a dipole.  
One part is partially positive and the other is partially negative in a dipole. In the absence 
of an applied electric field permanent dipoles exist, due to the differences in the electro-
negativity of the bonded atoms (e.g., carbonyl group, cyano group). An applied electric 
field creates induced dipoles, which causes redistribution of electrons shared between the 
bonded atoms with similar electro-negativity. The orientation process requires a 
characteristic time, called the dipole or molecular relaxation time and denoted by!![5, 6]. 
For Single surface and parallel plate electrodes, ε"and ε!can be calculated as 
follows: 
ε"= !"!!!!                                                                                                                              (3) 
ε! = !!"!!"#!                (4) 
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Where: 
C = capacitance (farads) 
 A = electrode plate area 
d= plate spacing  
R = resistance (ohms) [conductance = 1/R] 
f = frequency (Hz) 
εo= absolute permittivity of free space (equal to 8.85 x 10-12 F m -1) 
Debye developed an orientation mechanism assuming a single dipole or a single 
molecular relaxation time (!!) for all the molecules [7]. The classic Debye equations for 
ε"and ε!are as follows: ε′ = ! ε! + !!!!!!! !"!!! !                (5) 
Where: ε! = unrelaxed permittivity due to induced dipoles. ε! = relaxed permittivity.  !!!!!!! !"!!! != Permittivity due to alignment of dipoles ε!! = ! ε! + !!!!! !"!!!!! !"!!! !                (6) 
to account for conductivity, can be written as: ε!! = ! !!!!! !!!"!!! !!!"! ! + ! !!!"!!                                                                                                (7) 
Where: 
!!!!! !!!"!!! !!!"! ! =!Dipole loss factor term !!"!!! = Ionic conduction term ! = Ionic conductivity (mhos cm-1) 
Both loss factor and permittivity are frequency and temperature dependent.  
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Permittivity has low values for pharmaceutical materials, chemicals and polymers 
when measurements are performed at low temperature, below thermal transitions, 
because molecules are frozen in place and the dipoles cannot move to orient and align 
themselves in the direction of the electric field. When dipoles are excited by moderate 
frequencies, they have enough time to become oriented, and their permittivity is high 
while loss factor is low. But when the frequency becomes so high that the dipoles can no 
longer follow the field, the dielectric constant falls steeply and material shows dispersion. 
This phenomenon is also followed by a sharp increase in dipole loss, resulting in a peak 
in loss factor. It consists of two contributions: energy losses due to the orientation of 
molecular dipoles, and conduction of ionic species [5, 6, 8 & 9]. 
 The magnitude of the conductivity term relative to the dipole term can be 
adjusted by changing the frequency as the frequency is in the denominator of the ionic 
conduction term. At high frequency, the dipole loss factor term is dominant; at low 
frequency, the ionic conduction term is dominant.  Ionic conduction is not significant 
until the pharmaceutical material and polymer becomes fluid (e.g., above Tg or melting 
point). Therefore, ε!! represents the energy to align dipoles or move ions below and 
through Tg [5] 
Above Tg, ε!! can be used to calculate the bulk ionic conductivity as follows: ! = ε!!2!"ε!                                                                                                                      (8) 
Bulk ionic conductivity can be used to follow the physical transitions in the material that 
takes place during change in degree of alignment of dipoles and ion mobility. Ionic 
conductivity is related to viscosity, because fluidity is identified by the ease with which 
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charged ions usually present as impurities or polar constituents in drugs can migrate 
through the samples [5].  
The frequency dependence of ε! andε!!, can be illustrated by a preferred method -
Argand diagram (Known as Cole-Cole plot) [10]. Where ε!! is plotted vs. ε! taking ω as a 
parameter.  When the ionic conductivity!!(!) is zero, the Argand diagram corresponds to 
a Debye model is a perfect semicircle with intercepts ε!and ε! on the X-axis and with a 
maximum value of (ε! − ε!)/2, shown in (Figure 2.5.). The dielectric behavior of 
complex chemicals or polymers quite often can be characterized by a distribution of 
relaxation times rather than by a single relaxation time, leading to departure from a 
perfect semicircular arc, or appearance of more than one arc of relaxation times. As ! 
increases, the Argand diagram exhibits a vertical line with an intercept ε! at the ε! axis. 
This is due to conduction and interfacial (Maxwell-Wagner) polarization resulted from 
accumulation of charges at the electrode interfaces [5, 6 & 9]. 
 
Figure 2.5. Cole-Cole plots corresponding to the Debye curve 
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Practically, the observed Argand diagrams deviate from the ideal ones, due to 
various reasons: ionic conductivity, electrode polarization, the existence of more than one 
dipole relaxation time for most materials, thus originating a distribution of relaxation 
times, causing some differences between calculated and observed results.  
One of the principal difficulties associated with studying the dielectric behavior of 
solid samples is lack of generally agreed interpretive model. Several empirical 
corrections modify the Debye model, among these, those proposed by Cole–Cole [11], 
Davidson–Cole [12] and Havriliak–Negami [13-14]. The Debye model is, in practice, if 
ever applicable to solid systems, is based on the assumption of non- interacting dipoles. 
Cole and Cole noted that these general features of peak in dielectric loss and dispersion in 
the real part of the susceptibility are commonly observed and suggested that the 
discrepancy from the Debye model was due to the existence of more than one, almost 
overlapping dipole relaxation times. When one considers the physical basis of this 
distribution, it is because of inhomogeneities in the solid structure such as crystal defects 
or, a distribution of orientations of the molecules within that structure.  
Hill and Jonscher [15] criticized this approach on the basis that the widths of the 
relaxation peaks observed in practice are so great that the distribution of relaxation times 
would have to be extremely wide. An alternative and equivalent approach is to consider 
the dielectric behavior to be a function of the probability of charge hopping between 
specific sites in a solid or material, where the peak broadening is due to a distribution of 
probabilities [16-17]. 
The Polaron theory or the “hopping model for conduction” is used to describe the 
transfer of charge between various specific localized sites within a material under the 
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influence of an electric field. According to this theory a corresponding phonon field 
involving polar modes accompanies the transfer of electronic charge. This composite of 
the electron and the associated phonon field are treated as a quasiparticle, i.e., the 
Polaron. A slow moving electron in a dielectric induced crystal interacting with the lattice 
ions through long-range forces will be surrounded by a field of lattice polarization caused 
by the moving electron. The charge jumps or hops discontinuously from site to site [18]. 
2.2 Differential Scanning Calorimetry (DSC) 
DSC is by far the most popular thermal analytical technique for the 
characterization of pharmaceutical solids [1]. DSC monitors the energy required to 
maintain the sample and a reference at the same temperature as they are heated. The 
difference in energy is recorded as a function of temperature to give a DSC scan [19]. 
Heat flow corresponds to transmitted power and is measured in watts (W) or (mW) [20].  
2.2.1 Principle.  When the sample undergoes a phase transition or transformation, 
a heat difference occurs between the sample and reference. Therefore, a heat would either 
flow or get absorbed depending on whether the reaction is endothermic or exothermic. If 
the sample absorbs energy then the enthalpy change is called endothermic. If the sample 
liberates energy then enthalpy change is said to be exothermic. By recording the 
difference in the heat flow between the sample and the reference material DSC measures 
the energy difference of the sample. The result of a DSC experiment is a curve of heat 
Flow (W g-1) vs. temperature (o C) or vs. time (min) [21-23]. 
DSC measurements provide information on thermal effects, which are 
characterized by an enthalpy change and by temperature range, such as melting behavior, 
purity, crystallization, polymorphism, solid-solid transitions and chemical reactions.  
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Since DSC also measures the specific heat capacity, a change in heat capacity such as 
that occurs at glass transition can also be determined [20]. DSC is widely used in the 
pharmaceutical industry to characterize APIs (Active Pharmaceutical Ingredients) and 
excipients for purity determination, melting points, polymorphism behavior, 
crystallization, glass transition, crystalline and amorphous contents, and decomposition 
temperatures and more (see Figure 2.6.) [22].  
 
Figure 2.6. DSC profile for the amorphous form of an API 
 
2.2.2 Types of DSC. A DSC is available in two types: Heat-flux DSC and Power-
compensation DSC [24].  The principles of both techniques are outlined below. 
2.2.2.1 Heat-flux DSC.  Heat-flux DSC is rather similar to DTA. The big 
difference is that DTA does not allow quantitative measurements to be performed, while 
heat-flux DSC, owing to the well-defined thermal resistances in the cell, is eminently 
suited to this kind of measurement. (Formerly, heat-flux DSC was called quantitative 
DTA). 
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Figure 2.7. Schematic drawing of a heat-flux DSC cell; S: sample, R: reference [25] 
Sample and reference substance are place in small crucibles and positioned on   
heat-flux plate (Figure 2.7.). This plate generates a very controlled heat flow from the 
furnace wall to the sample and reference of changes in the thermal resistance of the 
sample is eliminated. In this way, enthalpy changes in the sample can be measured 
accurately. 
2.2.2.2 Power-compensation DSC.  Here, in contrast to heat-flux DSC, sample and 
reference are completely isolated from each other (Figure 2.8.). Both, the sample crucible 
and the reference crucible have their own heating element and temperature-sensing 
element. With the aid of a temperature programmer, both sample and reference are heated 
and always controlled to have the same temperature. As soon as changes in the sample 
occur, extra (in the case of an endothermic reaction) or less (with an exothermic reaction) 
heat will be needed to maintain the set-heating rate. With the aid of special electronic 
circuitry, extra (or less) power is now sent to the sample holder in order to keep the 
temperature difference zero [26]. In this way, power and consequently heat flow and the 
enthalpy changes are measured. 
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Figure 2.8. Schematic drawing of a power-compensation DSC cell: (Red) sample pan and (Blue) reference pan [27] 
Heat-flux and power-compensation DSC instruments in their modern form 
constitute very sensitive pieces of equipment, having the capacity to measure heat flow of 
the order of micro Watts. This feature makes the applicability of the technique almost 
unlimited: every physical change or chemical reaction takes place with a change of the 
enthalpy and consequently absorption or release heat [28].  
A characteristic DSC curve of an amorphous form of an API is shown in Figure. 
6. The temperature, is always, plotted on the x-axis and Heat Flow is plotted on y-axis. In 
this case a change in the specific heat leads to the baseline shift at about 61o C and 
corresponds to a glass transition. The first peak corresponds to an exothermic 
crystallization and the second peak to the endothermic melting of the substance (an API). 
According to the standards of the ICTA (International Confederation for Thermal 
Analysis), endothermic peak are plotted downward and exothermic peak upward. 
According to DIN (Deutsche Industrie Norm) standard 51005, endothermic peaks are 
plotted upward. Normally, every curve carries an indication of its mode or presentation.  
2.2.3 Applications.  There are a very large number and variety of applications of 
DTA and DSC. The applications may be divided roughly into two categories [26]: 
22 
1. Physical changes and measurements, such as melting, crystalline phase 
changes, changes in liquid and liquid crystalline states and in polymers, 
phase diagrams, heat capacity, and glass transitions, thermal conductivity 
and diffusivity and emissivity. 
2. Chemical reactions such as dehydration, decompositions, polymer curing, 
glass formation and oxidative attack. 
The numerous applications for DSC have been clearly cited in a number of reviews and 
research articles [26-28]. 
2.3 X-ray Powder Diffractometry (PXRD) 
2.3.1 Introduction. Diffraction techniques are perhaps the most definitive method 
of detecting and quantifying molecular order in any system. An x-ray diffraction study 
requires a clear understanding of the crystallographic structure, chemical composition, 
physical properties of solid, metals, films and other polymeric materials present in a 
given sample. It is a widely used in chemistry, material science, biology, geology and 
environmental science, forensic science, polymer science and pharmaceutical sciences. 
Other diffraction techniques that have been used to study order in pharmaceutical systems 
are as follows: conventional, wide-angle and small-angle diffraction techniques [29-30]. 
Conventional X-ray powder diffraction, also known as PXRD (see Figure 2.9.) can be 
used to quantify non-crystalline material and by controlling the temperature and 
environment it can also be used to follow the kinetic phase transformation. Small-angle 
X-ray diffraction technique measurements have been used to study the subtle structural 
changes in polymers. Although, these methods only “observe” molecular order, and the 
disorder in the system is predicted by the absence of the order [31]. PXRD is a rapid 
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analytical technique primarily used for phase identification of a crystalline material and 
can provide information on unit cell dimensions. Crystalline organic solids are made up 
of molecules that are packed or ordered in a specific arrangement. This molecular 
arrangement is defined as unit cell, which is the smallest repeating unit of a single crystal 
[32].  
X-Ray difraction (XRD) is most widely used in numerous industries for 
identification of crystalinity in compound by studying their difraction pattern. Some other 
specific benefits of XRD are listed below. 
• Single phase materials in several samples such as chemicals, ceramics, 
polymers, etc., are identified. 
• Determination of polymorphs. 
• Evaluating amorphous and crystalliine content in pharmaceuticals or other 
chemicals. 
• Recognition of multiple phases in samples like rocks, minerals, meltas, 
etc,. 
• Quantitative determination of different phases is possible by advanced 
technique called PXRD, which different phases by calculating peak ratios. 
In order to interpret the data obtained from XRD you need to know a few basic 
principles like how the X-rays interact with the sample, possible errors and the different 
source. The mathamatics and physics involved in generating the monochromatic X-rays 
and X-ray difracttion is not necessary. 
2.3.2 Sample preparation. The most critical factor in obtainig a quality 
analytical data relies on preparation of the specimen. In order to have a ideal sample 
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preparation you need to have random distribution of crystals which should be less than 
10µm. Specimen should be mounted such a way that there should be no crystallite. 
Considering the above factors sample preparation is considered to be a significant topic. 
2.3.3 Generate analytical x-rays. Experimental results are much better as we get 
closer to the monochromatic beam in our X-ray beam. In X-ray difracttion of most 
organic and inorganic crystals copper tubes are used. For copper the most stongest 
radiation (Kα) is 1.54 angstroms. There are low energy and high energy radiations 
produced by tubes. Kα1, Kα2 and Kβ are the high energy radiations of which we use Kα1 
for analytical data. A monochromator or an energy selective detector is used to eliminate 
Kβ, and Kα2 is electronically removed from X-ray data during processing. 
2.3.4 XRD Principle.  Sample is exposed to X-rays this interaction leads to 
secondary wave which is produced by the cones in the sample. According to the 
mathamatical equation Braggs law the produced secondary wave is related to the 
interplanar spacing in the crysalline sample. 
Braggs Law: 
nλ = 2d sinθ                                                                                                                       (9) 
Where n is an integer 
λ is the wavelenght of X-rays 
d is the interplanar spacing generating the diffraction 
θ is the diffraction angle 
 Diffraction maxima are measured along 2θ diffractometer circle for powder 
samples having infinet amount randomly oriented crystal. According to Braggs law the 
angle of diffraction is related to the interplanar spacing d, and the intensity of the 
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diffraction is related to the strenght of those diffractions in the specimen. Electronic 
detectors are used to measure and record angles and intensities of diffraction. Specialized 
software is utilized to create plots of 2θ (X axis) vs. intensity (Y axis) for the sample. 
Units for λ and d are measured in angstroms.  
 
Figure 2.9. Phillips X-ray Diffractometer [29] 
2.4 Scanning Electronic Microscopy (SEM) 
SEM was first build by Von Ardenne in 1938 later it was developed and described 
by Zworykin in 1942 [1,2]. A wide range of sample specimens can be analyzed to micro 
structural scale using SEM. You can have an image 500 times greater than light 
microscopy using SEM it gives a precise measurement of small objects down to 50nm. 
An electron beam with high energy is employed to illuminate the specimen and produce 
image on a fine scale. High-resolution images produced by SEM are used to analyze 
chemical structure, identify micrographic and crystallographic orientation of many 
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materials. A back-scattered image from SEM is used to identify phase in a multi-phase 
analysis.  
2.4.1 Instrumentation. Electron Guns: A stable source of electron beam is 
produced by electron gun. Field emission and thermionic emission are two strategies used 
to produce these electrons for electron beam. In thermionic electron gun a wire or any 
compound is heated to very high energies so that the electrons overcome the work 
function of cathodes and escape in to the source. The cathode filament is placed close to 
anode disc and maintained at a high negative voltage so that the produced electrons are 
accelerated easily. 
In field emission transport of electrons from the metal surface occurs as a result of 
delocalization. This transport of electrons by delocalization is known as tunneling effect 
[6]. 
2.4.1.1 Electron lenses. Magnets are used to manipulate configuration of electron 
beam. Condenser and objective lens de-magnify electron image formed at crossover of 
electron gun. In some cases demagnification is high as 10,000. Usually one or more 
lenses are utilized in the condenser lens, which determines the current impinging on to 
the sample while the final spot size is determined by objective lens. 
2.4.1.2 Detectors. Types of detectors used in SEM are (1) solid state detectors, (2) 
specimen current detectors, (3) scintillator photomultiplier detector, and (4) cathode 
luminescence detector [4]. 
2.4.1.3 Image processing. There are three basic ways to process image: (1) 
optical photographic method, which is a traditional method where image is printed using 
lens available in the photographic enlarger. (2) Electric analog method in which the 
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electric or analog is manipulated by the detection system in SEM. (3) digital image 
process this is much advanced technique with better grey definition, sophisticated storage 
methods and freedom from deterioration. 
2.4.2 Sample preparation. Preliminary treatment is required in many samples 
before mounting. Avoid volatile compounds, as they tend to vaporize. Conducting 
samples yield better images. Non-conducting samples require conductive coating. To 
prevent charging under electron beam sputter coating should be done. 
2.4.2.1 Sputter coating. Image quality in a non-conductor is affected as they tend 
to collect electrons from the electron beam and become negative. To prevent this samples 
are covered with a very thin layer of metals such as gold or silver. This process of coating 
is carried out in a glass chamber that is evacuated by rotary pump and argon gas is 
pumped to 0.1 torr pressure.  High voltage is applied to electrodes that bombard ions and 
sputtering of atoms on to the sample. Thickness of the atoms on the sample can be 
controlled (see Figure 2.10.).  To protect fragile material from electron bombardment 
cold sputtering is available.  
 
Figure 2.10. Sputter Coater 
When non-conductive specimens are ex mi ed in SEM they tend to coll ct electrons from the 
process of electron bombardment and become negatively charged, th reby imposing difficulties 
in imaging. To prevent this spec ens are made ele rically conductive by coating with metals 
such as gold, silver16 and old-palladium alloys. The equipment used is quite simple as we can 
see in Figure 5.3. The process is carried out in a glass chamber. The chamber is eva uated with a 
rotary pump and argon is pumped in through a needle valve to a pressure f about 10-1 torr. 
Specimens to be coated are attached to th  base pl te. W en high voltag  is applied across the 
electrodes, the metal f il target is bomb rded with ions and sputtering f the atoms occurs. These 
atoms are deposited onto the specimen with the thickness  being controlled  by the discharge 
current and time 17, 18. 
Currently, ld sputter coats are also commercially available which tend to protect the fr gile 
materials from elec ron bombardment18.
                    
                                                        Figure 5.3 Sputter Coater8
5.4 Working Method of SEM
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2.5 Macro-Photomicrography  
A Konica-Minolta DG SLR Camera with a 28-80 mm macro lens was used for 
Macro- photomicrography to characterize the crystalline and amorphous materials on the 
single surface interdigitated array gold electrodes, and material in the DSC pans. An 
eyepiece reticule was used to calibrate the Macro-photomicrography system. 
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CHAPTER III 
STANDARD TEMPERATURE CALIBRATION PROTOCOLS AND MATERIAL 
CHARACTERIZATION WITH PHARMACEUTICALS BY THERMAL 
ANALYSIS 
Manik Pavan Kumar Maheswaram 
(Manuscript submitted for publication and is under review) 
(Journal of Testing and Evaluation ASTM International) 
3.1 Introduction 
There are thousands pharmaceutical materials known today [1-3]. There is a need 
for each material that is synthesized and discovered, to be tested and standardized. 
Calibration typically uses metals e.g., Indium and Zinc to calibrate the three instruments 
described in this study [4]. In order to make DSC, DEA and TMA more user friendly in 
the pharmaceutical community, we have implemented the use of analytical grade APIs 
and excipients for temperature and material characterization as well as calibration. 
Calibration is performed by observing the melting transition temperature of standard 
pharmaceutical materials within the temperature range of interest.  DSC is used to 
determine the glass transition temperature, melting temperature, heat of fusion and heat 
of crystallization of pure materials. These first and second order thermodynamic
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transitions can also be delineated using pure drug samples. DEA is typically used to 
measure the ionic conductivity and dielectric properties of a broad range of materials [5]. 
TMA measures the dimensional variability of a solid polymer or material, and can also be 
used to characterize powdered APIs [6]. To design an efficient procedure for calibration, 
understanding the thermal analysis of all these instruments is crucial. 
 3.1.1 Differential Scanning Calorimetry. DSC is a thermal analysis technique 
used to measure the changes in the heat flow of a sample, which involves exothermic or 
endothermic processes, as a function of time and temperature. It is widely applicable to a 
variety of materials such as pharmaceuticals, polymers, ceramics, metals, food and 
inorganics etc [7-11]. DSC is a well-established tool for pharmaceutical or material 
analysis, and provides information regarding melting temperatures, heats of fusion and 
crystallization temperatures, glass transition, drug and excipient interaction, thermal 
stability of pure materials or APIs. These properties are crucial for pre-formulation and 
drug dosage design of pharmaceuticals. 
   The experimental variables considered while performing DSC are the sample 
size, environment, heating rate and pan type (open pan, closed pan etc.). The performance 
of DSC is dependent on all these experimental variables [2, 5-7]. The heat of fusion (Jg-1) 
is associated with the DSC examination of the crystalline API (Run 1). The thermal 
analysis curve represents a physical chemical property of the sample drug, i.e., melting. 
Cooling of the active pharmaceutical ingredient sample after melting through the 
crystallization yields the temperature and heat of crystallization (J g-1) and is needed to 
further characterize the APIs. 
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3.1.2 Dielectric analysis.  DEA is a material characterization technique used to 
measure quantitative thermal and dielectrical information on wide variety of materials, 
which include solid, liquids, films and polymers [12]. It can be used e.g., to determine the 
polymer viscosity, thermal transitions of polymers, characterization of food products and 
pharmaceuticals. As DEA is a thermal analysis tool it compliments DSC by allowing a 
measurement of molecular motion initiated by the A.C. electric field. 
3.1.2.1 Principle of dielectric analysis. An applied sinusoidal voltage on a sample 
placed on a single surface gold ceramic interdigitated electrode creates an alternating 
electric field, producing polarization in the sample that oscillates at the same frequency as 
the electric field. There is a phase angle shift δ measured by comparing the applied 
voltage to the measured current, which is separated into capacitive (e’) and conductive 
(e’’) components [13]. 
! Capacitance- High frequency permittivity (e’) or dielectric constant. 
! Electrical conductivity (pS cm-1) - Loss factor (e”) x Applied frequency 
(Hz) x 2π. 
      From known geometrical constants, such as electrode arrangement and electrode 
spacing of the IDA electrode, desired electrical properties of the test sample or material 
can be recorded. Such electrical properties are ionic conductivity, dielectric constant, 
dielectric loss angle, dissipation factor, dipole relaxation time, permittivity (e’), loss 
factor (e”) and tangent delta (e’’/e’). These properties are recorded as a function of time, 
temperature and frequency during the course of the experiment by varying and measuring 
these independent parameters [14-15]. 
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! Permittivity (e’) is a measure of the alignment of molecular groups 
(dipoles) in the electric field.  
! Loss factor (e’’) is a measure of the energy required to move the 
molecular groups or ions and is proportional to ionic conductivity. 
! Tan delta is the ratio of the loss factor divided by the permittivity; Tan 
delta = e’’/e’.   
3.1.3 Thermomechanical Analysis.  TMA is a thermal analysis technique used to 
measure changes in the physical dimensions (length or volume) of a sample as a function 
of temperature and time under a non-oscillatory load [6]. This technique is widely 
applicable to a variety of materials such as pharmaceuticals, polymers, ceramics and 
metals etc. TMA has been used in pharmaceutical analysis [17-19]. The variables 
considered while performing the thermal mechanical analysis are; applied load, gas 
environment, temperature range and heating rate as well as TMA probe type. The tests 
are run in a heating mode at a desired heating rate and temperature range of interest. 
Probe displacement profiles are subsequently analyzed in terms of coefficient of thermal 
expansion, softening and melting temperatures, and glass transition temperatures. 
Information obtained based on the different TMA probe types are shown in (Table 1), 
and recorded as a function of temperature. 
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Table 1  
Types of TMA Probes and Resulting Measured Properties 
TMA Probe Type Information Obtained 
Flat probe/ Light load Coefficient of Thermal Expansion and Tg 
Dilatometer Coefficient of Thermal Expansion and Tg 
Penetration probe/Significant load Softening/ Tg, Melting and creep modulus 
Tension accessory Tg, melting and cure behavior 
Parallel plates Melting, Viscosity and Gelation 
Flexure accessory Softening/ Tg and Melting 
                        *Tg =Glass transition temperature 
      The focus of this study is to extend the selection of calibration materials from 
metals to pharmaceuticals i.e., APIs for the three instruments described in this study. 
Primarily by introducing a modified ASTM standard where the temperature is calibrated 
with a current NIST (National Institute of standards and Technology) standard material in 
addition to the use of APIs. Our overall focus is to calibrate the temperature axis of DSC, 
DEA and TMA with the melting temperatures of APIs and excipients. These test 
protocols permit inter-laboratory and intra-laboratory comparison and correlation of 
instrumental temperature scale data within the pharmaceutical community, and would be 
more relevant to quality control scientists in the pharmaceutical industry. 
3. 2 Experimental 
3.2.1 Materials. The following analytical grade >99.9 % pure APIs and an 
excipient (Vanillin), within the temperature range of interest, were used in this test 
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development as listed in Table 2 with Chemical Abstract Service (CAS) registry 
numbers. The ASTM E928-08 “Standard Test Method for Purity by Differential 
Scanning Calorimetry” was employed to verify the purity of the test specimen used in 
this study [20].  
Table 2 
Calibration Materials and Their Transition Temperatures 
Calibration Materials* 
Literature Transition 
Temperatures/ °C 
(Solid - Liquid) 
Chemical Abstract 
Service registry numbers 
Acetophenetidin 132 – 138 62-44-2 [21] 
Acetanilide 113 – 116 103-84-4 [22] 
Vanillin 81 – 83 122-33-5 [23] 
Sulfa pyridine 191 – 193 144-83-2 [24] 
*Available from Sigma- Aldrich® 
3.2.2 Instruments.  The TAI DSC 2920 was used to measure the heat flow 
properties of calibration materials as a function of time and temperature. The test 
specimens of desired temperature range from 25 to 250 °C were heated at a rate of 5 °C 
min-1 with nitrogen gas purge of 50 mL min-1. Open or closed pans were used in this 
study. 
The TAI Dielectric Analyzer 2970 was used for dielectric analysis of the 
calibration materials (test specimen), possessing dielectric properties that undergo solid-
liquid or solid-solid transition, over a wide range of frequencies from 0.1 to 1000 Hz and 
temperatures from 25 to 250 °C. The test specimen was ramped at a rate of 5 °C min-1, 
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nitrogen gas purge at a flow rate of 50 mL min-1 and liquid nitrogen cooling when 
necessary. The single surface gold ceramic interdigitated (IDA) electrodes were utilized.  
The TAI TMA 2940 was used to measure the dimensional change (µm) of the calibration 
materials as a function of temperature. The test specimens, packed into a DSC aluminum 
pan were studied over a desired temperature range from 25 to 250 °C and heated at a rate 
of 5 °C min-1 with a nitrogen gas purge of 50 mLmin-1. Sample height was typically of 
0.9 to 1.3 mm was used in the study. 
3.2.3 Hazards.  This test protocol involves the use of hazardous materials, 
operations and instruments. It is the responsibility of the user to take care and establish 
appropriate safety practice and to determine the applicability of regulatory limitations 
prior to use, adaptation of ASTM method E1363 [6]. 
3.2.4 Sampling.  Calibration materials are analyzed by all the three instruments 
on “as received” basis. Since sample size is very small, care should be taken, so that the 
test specimens are homogeneous and representative of the sample. While performing 
DEA, the test specimen must cover the entire surface of the IDA electrode. The thickness 
of the test specimen should be at least 1.5 times of the IDA electrode spacing. For DSC 
and TMA sampling is done by packing the test specimen in a standard aluminum pan. 
3.3 Calibration 
Temperature signal from the instrument must be calibrated accurately over the 
desired temperature range, to obtain consistent results from different experimental 
conditions. Therefore, calibration is a basic process for any instrument in order to obtain 
accurate results. Calibrate the permittivity and temperature sensors of the DEA 
instrument using the procedure described by the manufacturer in the operator’s manual. 
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This test protocol was performed and developed by using Standard Test Method for 
temperature calibration of DSC, DEA and TMA, ASTM method E967 [4], E 2038 [5] 
and E 1363 [6], respectively. 
3.3.1 Experimental procedures for DSC, DEA and TMA.  
• Select the calibration material of known transition temperature listed in 
table 2. 
• For DSC, weigh 10 mg of test material into a clean, dry aluminum pan. 
The sample size for DEA is 20 to 40 mg. Care should be taken, so that the 
test specimen covers the entire surface of the IDA electrode. Sample 
height of 0.9 to 1.3 mm was used for TMA analysis. 
• Load the test material into the instrument chamber e.g., (DSC, DEA and 
TMA), and purge the instrument with dry nitrogen gas (99.99% purity 
purge gas) at constant flow rate of 50 ml min-1 throughout the experiment. 
• Set the initial temperature of the instrument to a value about 30°C below 
the estimated transition temperature of the test material, and allow it to 
equilibrate for 5 min at that temperature. 
• Initiate a temperature program at a constant heating rate of 3oCmin-1 to a 
temperature 20°C above the estimated melt transition temperature of the 
test material. 
• Note: When a DSC is used, run a Heat-Cool-Heat cycle for each test 
material. Cool the test material at 3°Cmin-1 through the crystallization 
exotherm until the baseline is re-established below the crystallization 
temperature. 
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• Note:  when a DEA is used, initiate the measurement of permittivity at a 
test frequency of 1,000 Hz and a set of frequencies (1, 10, 100, 1000 Hz). 
Record permittivity and log Permittivity, on a linear scale, as a function of 
temperature 
• Record the accompanying thermal curve by using the instrument software. 
• Repeat the procedure described above for other calibration materials 
chosen. 
3.4 Results and Discussion 
3.4.1 For DSC.  At a thermodynamic transition temperature, i.e. change in heat 
flow is marked by absorption (or release) of energy by the calibrants resulting in an 
endothermic (or exothermic) peak in the heating (or cooling) curve is recorded. 
• From the resultant DSC thermal curve, measure the temperatures for the 
desired points on the curve: Tm, Tmp, Tc, Tcp, Heat of fusion (Jg-1) and 
Heat of crystallization (Jg-1) for a pure calibration material.  
Tm = Extrapolated onset melt temperature 
Tmp = Melting peak temperature 
Tc = Extrapolated crystallization temperature 
Tcp = Crystallization peak temperature 
∆Hf = Heat of fusion  
∆Hc = Heat of crystallization 
      The DSC thermal curves of Acetanilide (see Figure 3.1.), Acetophenetidin (see 
Figure 3.2.) and Vanillin (see Figure 3.3.) are described respectively. These heat-cool-
heat plots show changes in the heat flow (W g-1) with respect to time and temperature.  
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Figure 3.1. Acetanilide DSC curve showing Tmp =116.31° C, Tcp = 81.50° C; Heat of Fusion for first endothermic 
peak ∆Hf = 143.9 Jg-1 and ∆Hf = 123.3 Jg-1 for second endothermic peak; Heat of Crystallization, ∆Hc= 112.1 Jg-1. 
 
 
Figure 3.2. Acetophenetidin DSC curve showing Tmp =136.25° C, Tcp =126.18° C; Heat of fusion for first 
endothermic peak ∆Hf=163.1 Jg-1 and ∆Hf = 152.8 Jg-1 for second endothermic peak; Heat of crystallization, ∆Hc = 
151.9 Jg-1. 
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Figure 3.3. Vanillin DSC curve showing Tmp = 83.08° C, Tcp = 38.33° C; Heat of fusion for first endothermic peak 
∆Hf = 149.0 Jg-1 and ∆Hf = 137.0 Jg-1 for second endothermic peak; Heat of crystallization ∆Hc=116.2 Jg-1. 
 
      A summary of the DSC melting and crystallization properties of calibration 
materials is cited in Table 3. 
Table 3 describes the Melting peak temperatures (Tmp), Crystallization peak 
temperatures (Tcp), Heat of fusion (∆Hf, Jg-1) Heat of crystallization (∆Hc J g-1) and % 
Crystallinity of calibration materials evaluated by DSC. 
 
 
 
 
  
42 
Table 3  
DSC Melting and Crystallization Properties of Calibration Materials  
Calibration 
materials 
Melting peak   
Temperatures/ 
Tmp °C Cryst peak 
Temperatures/ 
Tcp °C 
∆Hf (J g-1) 
∆Hc 
(J g-1) 
% 
Crystallinity 
(∆Hc/∆Hf)*10
0 
1st 
Peak 
2nd Peak 
1st 
Peak 
2nd 
Peak 
Acetanilide 116.31 116.58 81.50 144 123 112 78 
Acetophenetidin 136.25 136.61 126.18 163 153 152 93 
Vanillin 83.08 82.45 38.33 149 138 116 78 
Sulfapyridine 192 Tg= (62) 123 174 - 57 33 
Note: Tmp = Melting peak temperature. Tcp=Crystallization peak temperature. 
 
3.4.2 For DEA.  At the thermodynamic melt transition temperature, an abrupt 
change in DEA permittivity is observed. The instrument records the temperature 
observed for this transition. 
• From the resultant DEA thermal curve, following parameters are measured 
to determine the property variation associated with the transition; 
frequency, permittivity, log permittivity, temperature, derivative of 
permittivity and log permittivity with respect to temperature. 
• Plot the DEA thermal curves of test specimens in the following manner: 
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a) Plot permittivity vs. temperature and first derivative of the 
resultant curve  
A single frequency (1000 Hz) and a set of 4 frequencies   i.e. (1, 
10, 100 and1000 Hz) were used in evaluating each calibration 
material. 
b) Plot log of permittivity vs. temperature and first derivative of the 
resultant curve 
A single frequency (1000 Hz) and a set of 4 frequencies i.e., (1, 10, 
100, and 1000 Hz) were used in evaluating each test material. 
c) For both these calibration processes use the first derivative to 
determine the inflection point of the original thermal curve and this 
inflection point is used as first onset point. The second point is 
typically above the known transition temperature on the original 
thermal curve where the slope is constant. 
d) Employ the instrument software to determine the onset temperature 
and the calibrated temperature. 
The DEA curve of acetanilide showing the permittivity transition temperature for 
a single frequency (1000 Hz) run is described in (Figure 3.4.). Figure 3.5 describes the 
acetanilide derivative of permittivity transition temperature for a single frequency run 
when plotted vs. temperature.  Figure 3.6 describes the DEA Acetanilide curve showing 
Log permittivity transition temperature at 10Hz. Figure 3.7 describes the DEA acetanilide 
curve showing Derivative of log permittivity transition temperature at 1 Hz. 
 
44 
 
Figure 3.4. DEA curve of Acetanilide showing permittivity transition temperature (114.12 °C) for single frequency 
(1,000 Hz) run 
 
 
Figure 3.5. DEA curve of Acetanilide showing Permittivity and Derivative of Permittivity transition temperature 
(114.12 °C) for a single frequency (1000Hz) run 
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Figure 3.6. DEA curve of Acetanilide showing Log permittivity and Derivative of Log permittivity transition 
temperature (115.11 °C) at 10 Hz 
 
 
 
Figure 3.7. DEA curve of Acetanilide showing Log permittivity and Derivative of Log permittivity transition 
temperature (113.23 °C) at 1 Hz frequency 
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A summary of frequency used i.e. (single or set of 4 frequencies); permittivity and 
Log permittivity transition temperatures obtained from the DEA thermal curves of the 
calibration materials are listed in Table 4: Acetanilide; Table 5: Acetophenetidin; Table 
6: Vanillin; and Table 7: Sulfapyridine. 
Table 4  
DEA Permittivity and Log Permittivity transition temperatures of single (1000 Hz) and 
set of frequencies (1, 10, 100, 1000 Hz) of Acetanilide Tmp =113-116 °C 
Frequency/ Hz 
Permittivity Transition 
Temperatures/ °C 
Log Permittivity Transition 
Temperatures/ °C 
1000 Hz 114.2 113.0 
1Hz 115.6 113.3 
10 Hz 115.1 113.5 
100 Hz 113.9 114.0 
1000 Hz 114.1 114.0 
Average 114.6 113.7 
Std Deviation 0.80 0.34 
% Relative Error 0.70 0.26 
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Table 5  
DEA Permittivity and Log Permittivity transition temperature of single (1000 Hz) and set 
of frequencies (1, 10, 100, 1000 Hz) of Acetophenetidin Tmp = 132-138 °C. 
Frequency/ Hz 
Permittivity Transition 
Temperatures/ °C 
Log Permittivity Transition 
Temperatures/ °C 
1000 Hz 131.0 131.0 
1 Hz 132.5 132.3 
10 Hz 132.5 132.7 
100 Hz 132.6 132.5 
1000 Hz 132.7 132.7 
Average 132.6 132.6 
Std Deviation 0.09 0.23 
% Relative Error 0.66 0.17 
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Table 6 
 DEA Permittivity and Log Permittivity transition temperature of single (1000 Hz) and set 
of frequencies (1, 10, 100, 1000 Hz) of Vanillin Tmp = 81- 83 °C 
Frequency/ Hz 
Permittivity Transition 
Temperatures/ °C 
Log Permittivity Transition 
Temperatures/ °C 
1000 Hz 81.0 80.9 
1 Hz 82.3 80.8 
10 Hz 82.0 80.9 
100 Hz 81.3 80.8 
1000 Hz 81.0 80.9 
Average 81.5 80.7 
Std Deviation 0.90 0.18 
% Relative Error 1.09 0.22 
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Table 7 
DEA Permittivity and Log Permittivity transition temperature of single (1000 Hz) and set 
of frequencies (1, 10, 100, 1000 Hz) of Sulfapyridine Tmp = 191-193° C. 
Frequency/ Hz 
Permittivity Transition 
Temperatures/ °C 
Log Permittivity Transition 
Temperatures/ °C 
1000 Hz 192.0 191.0 
1 Hz 192.7 191.5 
10 Hz 192.8 191.0 
100 Hz 191.3 190.8 
1000 Hz 191.0 191.4 
Average 191.9 191.1 
Std Deviation 0.9 0.35 
% Relative Error 0.47 0.18 
 
3.4.3 For TMA. At the transition temperature of the test specimen, there is a 
change in dimensional variability and the instrument records a measured change in the 
coefficient of thermal expansion. 
• From the TMA thermal curve recorded, extrapolated onset temperature is 
measured. This is calculated by extending the pre-transition portion of the 
curve which to the point of intersection with a line drawn tangent to the 
steepest portion of the curve which describes the probe displacement [6]. 
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The thermal curves of Acetanilide (see Figure 3.8.) and Acetophenetidin (see 
Figure 3.9.), and Vanillin (see Figure 3.10.) recorded by the instrument are described 
showing the extrapolated onset melting temperature.  
 
Figure 3.8. TMA of Acetanilide curve showing the extrapolated onset melt temperature (115.51° C). 
 
Figure 3.9. TMA of Acetophenetidin curve showing extrapolated onset melt temperature (134.27° C) 
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Figure 3.10. TMA of Vanillin curve showing extrapolated onset melt temperature (83.46° C) 
A summary of TMA observed extrapolated onset temperatures of calibration materials 
and literature transition temperatures are cited in Table 8.  
Table 8 
Summary of TMA extrapolated onset temperatures of calibration materials and literature 
transition temperatures 
Calibration Materials* 
TMA 
Extrapolated Onset 
Temperatures/ °C 
Literature Transition 
Temperatures/ °C 
Acetophenetidin 134.27 132 - 138 
Acetanilide 115.51 113 -116 
Vanillin 83.46 81-83 
Sulfapyridine 192.78 191-193 
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A summary of DSC, DEA and TMA melting temperatures for the calibrants 
(API’s) studied vs. the standard literature melting temperatures values are given in Table 
9.  
Table 9  
Summary of DSC, DEA and TMA Results 
 
Calibration 
Materials* 
 
Literature 
Transition 
Temperatures
/ °C 
DSC Melting Peak 
Temperatures/ 
Tmp °C 
DEA Transition 
Temperatures/ °C 
TMA 
Extrapolated 
Onset 
Temp/ °C 
1st 
Peak 
2nd 
Peak 
Permit
-tivity 
Log 
Permittivity 
Acetophenetidin 132- 138 136.25 136.61 133.6 132.6 134.27 
Acetanilide 113 – 116 116.31 116.58 114.6 113.7 115.51 
Sulfapyridine 191 – 193 192 Tg= 62 191.9 191.1 192.78 
Vanillin 81 – 83 83.08 82.45 81.5 80.7 84.46 
*Available from Sigma Aldrich®, **CAS=Chemistry Abstract Service registry number. 
 
Figure 3.11. A correlation graph of Standard Literature Transition Temperatures vs. Average of DSC, DEA & TMA 
Melting Transition Temperatures of calibration Materials 
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3.5 Conclusions 
Statistical analysis of the results from the three methods (DSC, DEA and TMA) 
indicates a high correlation with known literature values. Acetanilide, Acetophenetidin 
and Sulfapyridine were quality API standards for calibration. Vanillin is a quality 
excipient calibrant.  The three drugs plus the excipient, studied for this standard protocol 
present outstanding list of viable temperature standards. Their observed melting transition 
temperature best correlates with the known literature transition temperature values. All, 
but Sulfapyridine, yielded melting -crystallization - melting properties that enhance the 
overall characterization of those drugs. The Tg, on the 2nd heat cycle, of Sulfapyridine at 
62oC supplied additional important thermal characterization data.  Permittivity is the most 
appropriate property to calibrate the temperature of DEA as it deals only with dipole 
variations. The ionic conductivity, though an interesting material property, is a function 
of multiple properties, that are dipolar and ionic. The R2 correlation value for known 
standard literature temperatures vs. DEA permittivity melting temperature for of single 
(1000 Hz) and set of frequencies (1, 10, 100, 1000 Hz) was 0.99. The R2 correlation 
value for known standard literature temperatures vs. TMA extrapolated onset 
temperatures was 0.999. The R2 correlation value for known standard literature 
temperatures value vs. DSC melting peak temperatures was 0.999. The average melting 
temperature (Tm) for DSC, DEA and TMA correlated with the melting temperatures 
(Tm) of the known literature values with an R2 of 0.999. (See Figure 3.11.) It is our quest 
to infuse these new ASTM type standard test protocols into the pharmaceutical industry 
for drug pre-formulation and dosage design of pharmaceuticals. These new 
pharmaceutical based test protocols, permit inter-laboratory comparison and intra-
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laboratory correlation of instrumental temperature scale data within the pharmaceutical 
community, and will be implemented in our chemical pharmaceutical research. 
The following ASTM methods were also reviewed in the course of preparing this 
text: 
• E794 Standard Test Method for Melting and Crystallization Temperatures 
by Thermal Analysis [25]. 
• E473 Standard Terminology Relating to Thermal Analysis [26]. 
• E691 Standard Practice for Conducting an Inter-laboratory Study to 
Determine the Precision of a Test Method [27]. 
• E1325-02 Standard Terminology Relating to Design of Experiments [28]. 
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CHAPTER IV 
CHARACTERIZATION OF CRYSTALLINE AND AMORPHOUS CONTENT IN 
PHARMACEUTICAL SOLIDS BY DIELECTRIC THERMAL ANALYSIS 
4.1 Introduction 
Riga et al. studied the extensive applications of dielectric analysis (DEA) 
including states of matter as amorphous/crystalline. They characterized drugs, excipients, 
transdermal patches, carbohydrates, proteins, amino acids, motor oil dispersants and 
surfactants as well as electro rheological fluids using A.C. electrical properties over a 
wide range of frequencies [1].  The importance of the amorphous state when studying 
bioavailability, dissolution, and the development of poorly water-soluble APIs has grown 
significantly over the recent years [2, 3]. There are two forms of solids: glassy and 
crystalline forms [4]. Glassy forms or amorphous solid forms generally exist in a variety 
of industrial fields or products, such as polymers and plastics, textiles, foods and 
pharmaceuticals, and in the manufacture of semiconductors, ceramics, metals and optical 
materials [2, 3]. With reference to a crystalline solid, an amorphous solid can be defined 
as a substance with short-range molecular order; in contrast a crystalline solid has long-
range order [2]. For this reason, some amorphous forms are considered as liquids 
although they can solidify by the removal of thermal energy or a solvent in a way that
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avoids crystallization [5]. In pharmaceutical research, the amorphous form of a 
pharmaceutical solid has been the most important aspect of drug development. The 
significance of amorphous solids is presently ever-increasing due to their value to the 
pre-clinical formulation scientists and in general to the pharmaceutical industry due to 
various advantages [3, 6, 7]: (i) a continuous increase in the development of a number of 
insoluble APIs; these glassy drug compounds are unique based on their methods of 
production and screening [8], (ii) The growing attention in regulatory evaluation and 
distinct economic aspects of pharmaceutical solids development [9], and (iii) The 
different polymorphs of APIs including the amorphous forms have different 
interconvertible physical and chemical properties [10] which exhibit different solubility 
and compressibility characteristics. Processing of an amorphous drug substance is 
relatively simple, and easy when compared to crystalline drug production [2, 3]. 
Amorphous forms can be produced by a variety of pharmaceutical techniques, 
such as granulation, compaction, freeze & spray drying, melt-quench cooling, and solvent 
evaporation method. These amorphous forms can be used for better solubility, dissolution 
and bioavailability [6, 11, 12]. The amorphous phase has higher energy with higher 
chemical reactivity and generally is less stable both physically and chemically than the 
corresponding crystalline phase. The stability of the amorphous form is the main issue 
when stored at temperatures close to the glass transition temperature, (Tg). The glass 
transition temperature is a key characteristic property of amorphous materials. 
Quantification of the amorphous fraction of an API can be better understood by 
determining the heat capacity change associated with the Tg [13]. In pharmaceuticals, 
amorphous solids have several useful properties and are used as both API and excipients 
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[3]. Some of the useful properties are higher water solubility, higher dissolution rate [14] 
(i.e. no lattice energy, which is a thermodynamic barrier to dissolution) [15], and better 
compression characteristics when compared to the crystalline forms [2, 3]. 
Although the amorphous form has some advantages over its crystalline 
counterpart, like higher free energy, lattice disorder, higher water solubility, and 
molecular mobility [6], the amorphous systems have seen limited commercialization due 
to its thermodynamic instability and higher chemical reactivity [11,12, 16]. The 
amorphous phase can also occur throughout the particle or solid, in the bulk or at its 
surface, which can be relatively distinguished by dielectric studies [17]. As the disordered 
portion is low, it’s difficult to detect [11, 12]. But these high-energy reactive portions 
may cause some significant changes in drug development like: improve product 
performance, high dissolution rate, decreased chemical stability, solid-solid transitions, 
and recrystallization during storage [11, 18]. Because of the amorphous phase 
thermodynamic instability, there can be an irreversible conversion of the metastable form 
to its stable crystal form during manufacturing or in normal storage. Loss of drug 
function can occur when the amorphous material transitions to another meta-stable form 
resulting in, for example, a varying dissolution rate of the original crystalline form [16]. 
      Therefore, one must find a reliable method to monitor and characterize the 
degree of crystallinity and the amount of disorder in the APIs during their pre-clinical 
drug development to ensure commercializable formulations [11]. To maximize the 
efficiency of the amorphous material and prevent transformation of the drug during 
storage, one needs to understand and characterize the kinetics of the crystallization 
process, and determine quantitatively the various parameters associated with nucleation 
61 
and crystal growth [16]. This need is based on a vigorous test method to monitor the drug 
throughout its shelf life to assure product safety and quality [18]. Pharmaceutical 
scientists are making an effort to develop alternative methods that are precise, reliable, 
and fast, which employ small samples for determining the crystallinity or low levels of 
amorphicity in the sample [12]. The degree of crystallinity methodology is extensively 
used to measure the relative crystalline/amorphous content in pharmaceutical materials 
[19]. Several analytical techniques currently employed in the pharmaceutical industry for 
quantifying, and/or characterization of crystalline and amorphous forms of 
pharmaceutical materials include: X-ray diffraction analysis (XRD), dielectric Analysis 
[20], solid state-NMR [21], FT–Raman [22], FT–IR [23], modulated differential scanning 
calorimetry [24], thermally stimulated current spectroscopy [11], isothermal 
microcalorimetry, and solution calorimetry.  
Morphological and thermodynamic transitions in drugs as well as their amorphous 
and crystalline content in the solid state have been initiated by thermal analytical 
techniques, which include DEA and thermal mechanical analysis [24, 25]. These 
techniques were used successfully to establish a structure vs. property relationship with 
the API of drugs [24, 25]. The main focus of this study is to develop a novel analytical 
protocol utilizing dielectric analysis to define and quantify the crystalline and amorphous 
content in pharmaceutical solids. These innovative techniques will give pharmaceutical 
scientists new insights in how to understand the nature and behavior of drugs in the solid 
state. Pharmaceutical solids studied by these methods have led to a better understanding 
of the chemistry and molecular mobility that relates to the structure of the drug. This 
information is of the utmost importance during pre-formulation studies of drug 
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development. DEA measures the crystalline solid and amorphous liquid API electrical 
conductivity at temperatures below and above the melting temperature [13-15]. DEA 
scans the electrical signals over a wide range of frequencies (e.g. 0.10 to 100,000 Hz). 
The DEA ionic-dielectric conductivity is repeatable and differentiates the solid crystalline 
drug with a low ionic-dielectric conductivity level (<10-1 pS cm-1) and a high ionic 
dielectric conductivity level associated with the amorphous liquid (>105 pS cm-1). 
Further, DEA measures changes in phase (solid to liquid) transitions, significant 
variations in conductivity related to the ionic dielectric behavior of melted drugs and loss 
of residual solvents as it is subjected to a periodic electric field.  
         Our new DEA protocols can detect the crystalline and amorphous phase 
repeatedly and rapidly based on the experimental frequencies, time and temperatures. 
This A.C. frequency based technique has the ability to differentiate surface vs. bulk 
amorphicity [25]. Typically surface analysis is best profiled at 0.10-1.0 Hz and bulk 
analysis is between 1,000 - 10,000 Hz. This methodology is quick and can summarize the 
relative low levels of non-crystalline and crystalline material, thereby increasing the 
sensitivity of this technique. 
4.1.1 Dielectric Analysis (DEA). Dielectric analysis (DEA) is a material 
characterization technique that provides scientists with quantitative thermal, rheological 
and dielectric information on a wide range of materials in their various forms, which 
include solid, liquids, pastes, films, polymers, and organic additives in lubricating oils 
[16]. It can be used to determine the flow, thermal transitions, degree and rate of cure in 
polymers, characterize food products, pharmaceutical materials, and dielectric properties 
of thermoplastics, composites, as well as adhesives and coatings [1].  
63 
As DEA is a thermal analysis tool, it is closely related to DMA (frequency 
dependent dynamic mechanical analysis), which measures mechanical properties of a 
material. While DSC measures heat flow through which the heat of fusion and transition 
temperatures can be determined. DEA compliments DSC by allowing a measurement of 
molecular motion based on its electrical properties. 
The theory of a dielectric or theory of dielectric analysis may be illustrated by the 
time – dependent electrical response of a sample placed on a single surface gold ceramic 
inter-digitated electrode when an alternating (sinusoidal voltage) electric field is applied.  
This process produces polarization within the sample, causing oscillation at the same 
frequency as the electric field but with a phase angle (or phase shift) δ. This phase angle 
shift can be measured by comparing the applied voltage to the measured current [1 and 
24]. The current is then separated into capacitive (e’) and conductive (e’’) components.  
 The two fundamental characteristics of a material measured through dielectrics: as 
a function of time, temperature, and sampling frequency are: 
! Capacitance = High frequency permittivity (e’) or dielectric constant. 
! Electrical conductivity (pS cm-1) = Loss factor (e”) x Applied freq (Hz) 
x2π 
         The capacitive nature of the material allows or has an ability to store an electrical 
charge and this nature dominates the electrical response at low temperatures. The 
conductive nature of the material has an ability to transfer an electric charge and this 
factor becomes very important when the solid material is heated above its melting 
temperature to the liquid state. These electrical properties are significant since they have 
been related to molecular activity, allowing for probing the chemistry, and molecular 
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mobility of polymers and pharmaceutical materials. DEA reports three main electrical 
signals over a wide range of frequencies (e.g. 0.10 to 100,000 Hz): 
! Permittivity (e’) is a measure of the induced dipoles and alignment of 
molecular groups (dipoles) in the electric field.  
! Loss factor (e’’) is a measure of the energy required to move the 
molecular groups or ions and is proportional to ion conductivity. Ionic 
conductivity is associated with the viscosity of the sample because fluidity 
is identified by the ease with which ionic components can migrate through 
the sample under the applied electric field. 
! Tan delta is the ratio of the loss factor divided by the permittivity. Tan 
delta = e’’/e’.  Tan delta values are related to molecular mobility, response 
time to an electric field, and are related to polarization or relaxation of 
excited molecules or a measure of charge transfer properties [1, 24]. 
We developed a novel combined DEA-DSC protocol to evaluate 
amorphous/crystalline content in pharmaceutical solids. The DSC analysis will be used in 
two different protocols (a) Heat cycle only to measure the temperature range for heating 
to aid DEA evaluation. (b) Heat and Cool cycle to evaluate % crystalline and % 
amorphous based on the fusion and crystallization heats. 
The focus of these new methods is to determine the relative amounts of 
amorphous and crystalline content in APIs. Pharmaceutical scientists working on pre-
formulation of pharmaceutical drugs as well as those developing quality control of 
manufactured drugs need new information on the content of amorphous/crystalline 
matter. This new knowledge is to improve quality and stability of pharmaceuticals for the 
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consumer. There is a clear rationale for developing these new methods to better 
understand the effects of the total chemical structure on drug treatment including 
amorphicity. It is logical that electrical conductivity methods are implemented now since 
we have discovered significant variations in pharmaceuticals using DEA.   
4.2 Methodology 
Two novel DEA protocols were developed to determining the amorphous and 
crystalline content in pharmaceutical drugs. The first method is “The Empirical 
Method”. It is semi-quantitative method that is based on the observed significant 
electrical conductivity difference between the amorphous liquid (107 pS cm-1) and 
crystalline solid (10-2 pS cm-1). The second method is the “Activation Energy Method” 
and is more quantitative in nature. In this method the Activation Energy, Ea (J mol-1), is 
calculated from the DEA ionic conductivity. It is based on the fact that the relative Ea for 
the electrical reactivity (charging or charge transport) in the solid state of the amorphous 
phase is higher and conversely the Ea is lower (typically 30 -110 J.mol-1) and the 
electrical reactivity of the solid state for crystalline phase is low and conversely the Ea is 
higher (typically 1,200-2,000 J mol-1). 
4.2.1 Empirical method protocol. The empirical method to determine crystalline 
and amorphous content in pharmaceutical solids is as follows: First, a pure drug (100% 
crystalline) similar to the drug with unknown content is examined by DEA as a standard. 
For the pure drug prepared by the pharmaceutical company the % content before the 
melting temperature is 99.99-100% crystalline and with complete melt it is 100% 
amorphous in the liquid phase. Then, DEA re-run of the sample is performed to analyze 
the drug with the unknown amorphous/crystalline content. A combined DEA model plot 
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for the % content of an unknown drug and the pure drug is shown in the graphical 
representation (Fig.1) as log ionic conductivity vs. temperature. Next, a temperature, Ts, 
is selected ≤ 30 to 50o C below the melting temperature (Tm) of the drug from the 
overlayed DSC curve. Then, the linear distance (Δ3) in millimeters of log ionic 
conductivity on the y- axis is measured from 100% solid crystalline line (point X) to the 
100% amorphous line (point Z) at the selected temperature Ts. The 100% amorphous or 
liquid region is a hypothetical region and the 100% amorphous line is obtained by 
extrapolating the liquid region log ionic conductivity of the DEA plot. Next, the linear 
distance (Δ2) in millimeters of log ionic conductivity on the y- axis is measured from the 
semicrystalline line (point Y) to the 100% amorphous line (point Z)) and (Δ1) in 
millimeters from 100% solid crystalline line (point X) to semicrystalline line (point Y)) at 
the temperature Ts are measured. In the semicrystalline region the ratio of amorphous to 
crystalline content is not known. 
           The linear log conductivity distance in millimeters is a measure from the 
crystalline phase to the amorphous phase, which is equated to 100%. The Amorphous and 
crystalline contents can be calculated from the following equations and Figure 4.11. 
          % Amorphous = ∆1/∆3 x 100  
          % Crystalline = ∆2 /∆3 x 100 
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Figure 4.1. Graphical representation of DEA Empirical method 
 
4.2.2 Activation energy method.  A second method was developed based on a 
measurement of a DEA Activation Energy Ea (J mol-1) to determine the amorphous and 
crystalline content in drugs by dielectric analysis. Sharma and Yashonath [26] 
investigated ionic transport in a variety of inorganic amorphous glasses (solids). They 
observed a strong correlation between ionic conductivity and activation energy. Further, 
they found that higher conductivity is associated with lower activation energies and lower 
conductivity is associated with higher activation energies. Their results suggest that there 
is a strong relation between microscopic structure of the amorphous solid, ionic 
conductivity and activation energy [26]. 
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The Ea (J mol-1) calculation is more quantitative and is based on the relative 
activation energy for the electrical reactivity (charging or charge transport) in the solid 
state. The amorphous phase reactivity is higher (ca. 107 pS cm-1) and conversely the Ea is 
lower (frequency at 1 or 5 Hz typically: 60-200 J mol-1) measured as the slope of the log 
ionic conductivity vs. reciprocal temperature (K-1) of an Arrhenius plot and as a function 
of frequency (Hz). The reactivity and conductivity (typically 10-2 pS cm-1) of the solid-
state crystalline phase is lower and conversely the Ea is higher (typically measured by 
DEA at a frequency of 1 or 5 Hz: 1,200-2,000 J mol-1), also measured by DEA 
conductivity vs. reciprocal temperature (K-1) [27 - 29]. 
4.2.2.1 Activation Energy Ea (J mol-1) Protocol. 
1. Record a DEA curve of a pharmaceutical solid sample at a heating rate of 
10 oCmin-1 in a nitrogen flow of 60 mL min-1; a sample size of 20 mg. 
Heat to 20-30o C above the peak melting temperature recorded in the DSC 
curve.  
2. Plot the Ionic conductivity, pmho/cm vs. Temperature at fixed frequencies 
of 0.10 to 1.0 Hz. 
3. Measure the Ionic conductivity responses at < 30o C below the DSC 
melting point temperature. 
4. From the measured responses plot an Arrhenius plot of DEA log ionic 
conductivity vs. (K-1) x 1000 and perform a linear curve fit to determine 
the equation of the line. The slope of the linear curve fit is Ea R-1and it 
must be multiplied by 19.14to convert the slope value into Ea (J mol-1). 
Note: Ea is the activation energy and R is the gas constant of 8.314 J K-
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1mol-1 and one must include the conversion of natural log (ln) to log base 
10, which is 2.303. 
Ea (J mol-1) = (slope of the line) x 8.314 x 2.303  
5. The Ea (J mol-1) is inversely proportional to the concentration of the 
amorphous phase in the pharmaceutical sample. Relatively, the lower the 
Ea corresponds to a higher the ionic conductivity. The 1st DEA run 
resulting in log conductivity vs. Temperature yielding % crystallinity 
based on the DSC purity by Heat of Fusion (Jg-1). For an API the % 
crystallinity is probably 100% for the 1st sampling by DEA. For the 2nd 
and 3rd runs, samplings of the same API it will be less crystalline and 
more amorphous, based on a lower Ea (J mol-1) value. 
4. 3 Experimental  
4.3.1 Drugs.  The following drugs were evaluated in this study: Lidocaine (Tm, 
68o C), Lidocaine HCl (Tm, 74-79o C), Sulfapyridine (Tm, 192o C), Indomethacin (Tm, 
155o C), and Acetophenetidin (Tm, 135o C). All the drugs were obtained from Sigma-
Aldrich® and meet the USP (United State Pharmacopeias) testing specifications. 
Quetiapine fumarate (Seroquel®) (Tm, 173o C), and Procainamide HCl (Tm, 169o C) were 
purchased from Haorui Pharma-chem Inc. Edison, NJ. 
4.3.2 Experimental procedure.  A TAI 2920 DSC (TA Instrument) was used to 
profile the drug solid-solid transitions, melting, glass transition (Tg), and crystallization 
properties of the drugs. All the samples were ramped at a rate of 10oC/min in purged 
nitrogen gas flow at a rate of 60 mLmin-1 during heating and cooling cycles. The DSC 
aluminum pan weighed 13-14 mgs. Samples in the range of 8-10 mg were weighed using 
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the Mettler AT261 Delta Range® microbalance and loaded into an aluminum pan then 
closed and crimped. Temperature range was typically from room temperature to 30o C 
above the peak melting temperature (Tm) for the drugs under study. Heat flow (W g-1) 
values versus temperature and time were generated using the (TA Thermal Advantage) 
Universal Analysis 2000 software. The DSC instrument was calibrated using Indium as a 
standard according to ASTM standard test protocol E967. 
A TAI 2970 DEA (TA Instrument) was used to determine the electrical 
conductivity and Tan delta curve for each drug studied. For each solid powdered drug, a 
sample of approximately 20 mg was placed on a single surface gold ceramic 
interdigitated sensor. The samples were ramped from room temperature to 30o C above 
the melting temperature of the drug at heating rate of 10o C min-1.  A purge gas of 
nitrogen gas flowed at the rate of 60 mL min-1. The gold ceramic interdigitated sensor 
was calibrated by the fixture supplied by TAI. The DEA instrument was further 
calibrated according to ASTM E2038 Standard Test Method for Temperature Calibration 
of Dielectric Analyzers. This standard method was employed for all the drugs studied at 
5o C and 10o C min-1. Dielectric analysis was used to evaluate the electrical properties of 
the drugs. The conductivity measurements were recorded at controlled interval 
frequencies ranging from 0.10 to 10,000 Hz for all temperatures. 
A Konica-Minolta DG SLR Camera with a 28-80 mm macro lens was used for 
Macro- photomicrography to characterize the crystalline and amorphous materials on the 
single surface interdigitated array gold electrodes, and samples on the DSC pans. An 
eyepiece reticule was used to calibrate the Macro-photomicrography system. 
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4.4 Results and discussions 
We tested the applicability of the novel empirical method with several model 
pharmaceutical APIs. When Lidocaine is heat cycled through the melt and then cooled 
back to room temperature. The 1st DEA run of Lidocaine reveals the crystalline to 
amorphous phase transition and change in the ionic dielectric conductivity from ≤ 10-2 
(pS cm-1) for the crystalline phase and 105 (pS cm-1) for the amorphous phase. Figure 2 
shows the DEA surface analysis profile for Lidocaine at 0.5Hz.  Low frequency DEA is 
confirmed as measurements at the electrode surface e.g. 0.5 Hz. The Lidocaine (Sigma 
Aldrich®) sample is initially 99.99% crystalline with very low ionic conductivity for the 
1st run and upon cooling and reheating a huge increase in ionic conductivity was 
observed. The 2nd and 3rd runs commensurate with an increasing ionic conductivity value 
of 103 pS cm-1 (79% amorphous) and 105 pS cm-1 (91% amorphous) see Figure 4.2. & 
4.3.  Figure 4.3 summarizes the % crystalline and % amorphous content in Lidocaine at 
0.1, 0.5 and 1.0 Hz by the DEA “Empirical” method. Figure 4.4 summarizes the % 
crystalline and % amorphous content in Quetiapine Fumarate (Seroquel®) at 0.1, 0.5 and 
1.0 Hz by the DEA empirical method. Table 1 shows the list of drugs tested and 
evaluated for crystalline and amorphous content by the proposed method (Table 1).  
 
72 
 
Figure 4.2. DEA Surface Analysis of Lidocaine at 0.5Hz (1st, 2nd & 3rd Runs); DSC Tm 69.89o C 
 
 
Figure 4. 3. Determination of % Crystalline and % Amorphous content vs. Frequency/Hz for Lidocaine at 0.1, 0.5 & 
1.0 Hz (Run1 to Run3) by the DEA Empirical method 
% amp = % Amorphous Content; % cry = % Crystalline 
Content 
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Figure 4.4. Determination of % Crystalline and % Amorphous content vs. Frequency/Hz for Quetiapine Fumarate at 
0.1, 0.5 & 1.0Hz (Run 1 to Run 3) by the DEA Empirical method 
 
 
 
 
 
 
 
 
 
 
 
% amp = % Amorphous Content; % cry = % Crystalline Content 
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Table 1  
Quantification of Crystalline and Amorphous Content in various Pharmaceutical APIs by 
DEA Empirical method 
Drug Average content of 2nd and 3rd DEA Runs at 0.1,0.5 and 1.0 Hz 
 % Crystalline Content % Amorphous Content 
Sulfapyridine 9 81 
Quetiapine Fumarate 10 90 
Lidocaine 13 87 
Procainamide HCl 19 81 
Lidocaine HCl 24 76 
Indomethacin 26 74 
Acetophenetidin 78 22 
 
Our second method to determine crystalline and amorphous content through the 
measurement of DEA activation energies was tested with several model pharmaceutical 
APIs.  Results for Lidocaine and Acetophenetidin are discussed as follows. Analysis of 
the Lidocaine by the proposed DEA empirical method yields a supportive interpretation 
of the activation energy method, i.e. determination of the % crystalline and amorphous 
content in a drug. Other APIs successfully tested by the activation energy method are 
Sulfapyridine, Quetiapine Fumarate (Seroquel®), Procainamide HCl, Lidocaine HCl and 
Indomethacin.  
 A plot of the DEA Log Ionic conductivity (pS cm-1) vs. Temperature (o C) for 
crystalline Lidocaine is summarized in Figure 4.5. For the first run, we observed a slow 
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rise in ionic conductivity till 60o C, (10-2 pS cm-1) followed by a very rapid increase (105 
pS cm-1) from 60o C to 90o C. The DSC-DEA curve overlay maps out the melting 
transition that occurs at 67o C. The second run cycling after the initial heat curve 
produced a ionic conductivity response that was enhanced due to the formation of the 
amorphous phase in Lidocaine, was observed from the temperature range of 40-70o C. 
The slope of the first curve was steep and decreased significantly in the second and third 
run. The slope change tracked the decreasing activation energy with each heat cycle. The 
ionic conductivity increases proportionally with the enhanced amorphous content. A 
curve fit of the log ionic conductivity vs. the reciprocal temperature in Kelvin produces a 
linear curve with a correlation coefficient of R2= 0.999 and a varying activation energy, 
for Lidocaine (Run 3) the Ea is 27 J mol-1 (see Figure 4.6.) for details.  Table 2 
summarized the Lidocaine data in triplicate for the DEA Activation Energy method and 
the determination of the % crystalline and amorphous content produced by a heat cycle at 
three frequencies, 0.1, 0.5 and 1.0 Hz (all frequencies are associated with occurrences at 
the sensor surface). The 2nd and 3rd runs produced an amorphous content of 93% at 0.1 
Hz, 94% at 0.5 Hz and 1.0 Hz, (see Table 2).  
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Figure 4.5. Lidocaine DEA and DSC curve overlay and comparing ionic conductivity in crystalline and amorphous 
samples by activation energy method at 0.1 Hz to 1.0 Hz (Run1, Run 2 & Run 3); Tm= 69.89o C 
 
 
Figure 4.6. Log conductivity (k) vs. 1/T (Kelvin) x 1000 for Lidocaine (Run 3, 0.1Hz); Ea = 27 J mol-1 
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Table 2  
Lidocaine DEA Activation Energy (J mol-1), % Crystalline and % Amorphous Content 
for 1st, 2nd and 3rd Runs at 0.1, 0.5 and 1.0 Hz frequencies 
Frequency/ Hz Run Ea/J mol-1 % Crystalline Content 
% Amorphous 
 Content 
0.1 1 480 100 0 
0.1 2 35 7 93 
0.1 3 35 7 93 
0.5 1 435 100 0 
0.5 2 30 7 93 
0.5 3 29 6 94 
1 1 419 100 0 
1 2 29 7 93 
1 3 27 6 94 
 
Evaluation of Acetophenetidin by the proposed DEA method for amorphous-
crystalline content was an outlier in this protocol, since this drug recrystallizes 
significantly while the other 6 drugs did not recrystallize to a noticeable extent. The 
activation energy for Acetophenetidin described in (Figure 4.7. and 4.8.) yielded a high 
value of 1240 J mol-1 at low ionic conductivities. It is our interpretation that this drug 
continues to recrystallize and therefore the method to quantify the concentration ratio of 
crystalline to amorphous varies. The 2nd and 3rd run produced varying values for the % 
amorphous and % crystalline content with frequency. The content was frequency 
78 
dependent for this drug but none of the other drugs evaluated. The 2nd and 3rd runs 
produced an amorphous content of 25, 49 % for 0.1 Hz, 58, 70% for 0.5 Hz and 46, 69% 
for 1.0 Hz, respectively. 
 
Figure 4.7. Acetophenetidin DEA and DSC curve overlay and comparing Ionic conductivity in crystalline and 
amorphous samples by activation energy method at 0.1 Hz to 1.0 Hz (Run1, Run 2 & Run 3); Tm= 135.80o C 
 
Figure 4.8. Log conductivity (k) vs. 1/T (Kelvin)*1000 for Acetophenetidin (Run 1, 0.1Hz); Ea = 1244 J mol-1 
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Quantification of the amorphous and crystalline content of the drugs studied by 
the DEA Activation Energy Method is summarized in Table 3. A correlation was 
established between the Empirical method & Activation Energy method resulting in the 
correlation coefficient of R2= 0.925 for the overall average % amorphous content of all 
the drugs studied (See Figure 4.9.).  
Table 3 
Quantification of Crystalline and Amorphous drug content of various pharmaceutical 
APIs by the DEA Activation Energy Method 
 
Drug Average content of 2nd and 3rd DEA Runs at 0.1,0.5 and 1.0 Hz 
 % Crystalline Content % Amorphous Content 
Lidocaine 7 93 
Sulfa pyridine 9 81 
Quetiapine 
Fumarate 
11 89 
Procainamide HCl 19 81 
Lidocaine HCl 22 78 
Indomethacin 24 76 
Acetophenetidin 47 53 
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Figure 4.9. A correlation graph of Empirical Method versus Activation Energy Method (Ea) for the overall average % 
amorphous content of all the drugs studied 
 
Semi-qualitative evaluation of the amorphous and crystalline states by macro-
photomicrography clearly denotes the two phases, (see Figure 4.10.) for Sulfapyridine at 
2.4X magnification. See Figure 4.11. for amorphous melt of Lidocaine HCL after 3rd run. 
All Pharmaceutical solids used in this study were characterized by this method. This 
material characterization technique aids the development of the DEA methods for 
identifying amorphous and crystalline character of the drug.  
 
Figure 4.10. Macro photograph of DEA electrodes with sulfa pyridine in Crystalline Powder form (Right), and 
amorphous form (left) at 2.4 X magnification 
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Figure 4.11. Macro photograph of DEA electrode with amorphous melt of Lidocaine HCl after 3rd Run 
4.5 Conclusions 
The most prominent conclusion is that we now have quantitative methods for 
determining the crystalline and amorphous content of pharmaceutical solids by dielectric 
analysis. We are basing this conclusion on the facts that the APIs distributed by 
pharmaceutical companies are ≥ 99.99% pure crystalline solids. Once the crystalline state 
is completely lost during melting the material becomes 100% amorphous. 
 Our studies reveal that 6 out of the 7 drugs evaluated showed this behavior of 
complete amorphous formation. In the case of Acetophenetidin, it recrystallized rapidly 
while the others remained predominantly amorphous. The crystalline and amorphous 
content of the drugs as determined by the empirical method was frequency independent. 
The frequencies studied relate to surface analysis at 0.1 - 1.0 Hz. The crystalline and 
amorphous content of the drugs as determined by the activation energy method was 
frequency dependent for one drug, i.e. Acetophenetidin. Therefore, Acetophenetidin was 
an outlier for these methods. DEA for the first run of the APIs is 100% crystalline with 
lower ionic conductivity and high activation energy, e.g., Acetophenetidin 1,200 -1,800 
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Jmol-1. The second and third run of this drug showed repeatable variations with higher 
ionic conductivity and lower activation energy observed from 470 to 930 J mol-1. The 
other drugs investigated yielded a stable activation energy e.g. for Lidocaine crystalline 
form it was 480 J mol-1 initially and for the amorphous form it was 27 J mol-1 at 1.0 Hz.  
 A comparison of overall average amorphous content by the Empirical method had 
a linear relationship with the Activation Energy method with a correlation coefficient of 
R2 = 0.925. The correlation coefficient for overall average crystalline content was R2= 
0.94. After calibrating the DEA instrument, examining a 10 mg sample with a heating 
and cooling profile plus interpretation time will lead to a definitive amorphous content in 
one hour. Marco-photomicrography aids the DEA interpretation as an opaque solid 
material as crystalline solid against the transparent amorphous material. These methods 
determine the % amorphicity and % crystallinity and are significant contributions to the 
analytical science of pharmaceuticals.  
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CHAPTER V 
PHYSICAL AND CHEMICAL CHARACTERIZATION OF HYDROCHLORIDE 
SALTS OF DRUG SUBSTANCES BY DIELECTRIC AND CALORIMETRIC 
ANALYSIS 
5.1 Introduction 
The critical factors for drug development of pharmaceutical formulations are the 
solid-state properties of drug candidates. These solid-state properties are crucial in 
selecting the appropriate salt form of a drug molecule as more than 50% of all the drugs 
molecules used in the medicinal therapy are administered as organic salts [1-6]. For 
large-scale production of the pharmaceutical formulations these salts of drug substances 
must be suitable and technically feasible and its solid-state properties maintained batch 
wise as well as over time. Changing salts in the middle of a development program may 
require repeating most of the studies performed initially, i.e., biological, toxicological, 
formulation, and physical and chemical stability.  
However, selection of a nonoptimal salt may lead to increased developmental and 
production costs, even product failure. Appropriate salt selection during the drug 
development process can significantly reduce time to market and will avoid these 
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problems and facilitate downstream development activities [2]. Salts are mainly used to 
alter the physical, chemical, biological, and economical properties of a drug substance. 
Salts with advantageous properties are usually patentable as new chemical entities. A 
major reason for choosing a salt form is based on a needed change in the solubility of a 
drug substance.  Substances containing free acid and base groups have poor aqueous 
solubility.  
However, with the saltification (i.e., salt formation) of these acid and base groups 
one can improve solubility, leading to greater bioavailability. The chloride, hydrogen 
sulfate, phosphate, sodium, and potassium salts exhibit significantly higher solubility and 
dissolution rates than the parent drug. In addition, salts usually exhibit a higher melting 
point and improved chemical stability compared to the parent drug (free acid or base), 
leading to greater stability and easier processing [4]. A choice of salts can also expand the 
formulation options for a material. For example Lidocaine, a compound limited to 
parenteral and topical formulations can be expanded to oral administration by changing it 
to a salt form (e.g. Lidocaine hydrochloride) with acceptable physical properties [7]. The 
different salts are different entities with altered behavior in the solid-sate and also in the 
liquid state. These properties have to be studied taking into account thermodynamic, 
surface, packing, mechanical and kinetic factors.  
The most pertinent solid-state properties may affect the melting, heat capacity, 
crystallinity and/ or amorphicity, conductivity, bioavailability, pharmaceutical 
processing, toxicity, therapeutic efficacy, quality, solid-state reactions, reactivity, and 
stability of the drugs [8-14]. The International Conference on Harmonization (ICH) 
requires proper investigations and analytical methods for drug substances and drug 
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products following a decision tree (ICH) Q6A [15]. A number of analytical techniques 
are commonly used for characterization of the salt of the drug substance: They are 
thermal analysis, microcalorimetry and combined techniques, X-ray diffraction, solubility 
and stability studies.  
Salt formation involves proton transfer from the acid and base entity. 
Theoretically, any substance or compound that exhibits acidic or basic characteristics can 
form salts. The major consideration is the relative acidity and/ or basicity of the chemical 
species involved. When using basic excipients in a formulation the relative acid/base 
strength of the resulting salt and its tendency to disproportionate should be considered. A 
common salt choice for basic drug substances approved by FDA is the hydrochloride 
(most encountered anion is chloride), mainly because of its availability and highly polar 
nature. However, due to the common ion effect, reports have shown that hydrochloride 
salts do not always increase the solubility of poorly soluble basic drugs [16-19].  
Thermoanalytical methods have been used in the pharmaceutical area for 35 
years. They are employed for quality control, preformulation, drug-excipient interactions 
and purity studies of raw materials and pharmaceutical products [20-24]. Thermal 
analysis techniques mainly (DSC, DEA and TG) play an important role in the detection 
of unexpected phase transitions and for the comparison of the suitability of the salt 
candidate prepared from the salt selection [25]. The observance of the thermal phase 
transitions by DSC is insufficient to fully characterize the behavior of a substance on 
heating. The formation of hydrates and solvates can be investigated using 
Thermogravimetry (TG). Other information, such as crystallinity and/ or amorphicity, 
90 
conductivity, solid-state reactions, reactivity, physical and chemical stability of drug salts 
can be obtained from dielectric analysis [26-29].  
The pharmaceutical industry relies mainly on solid salts; primarily crystalline 
forms for the delivery of the APIs because they are thermally stable, there are easy to 
handle, and they are pure. In contrast, amorphous drug formulations are rarely found. 
Salts in the crystalline form tend to melt and decompose, while salts in the amorphous 
form have a glass transition (Tg) and no defined melt. However, crystalline solid forms 
have low solubility and low bioavailability, compared with an amorphous form. 
Amorphous forms have enhanced molecular mobility (poorer physical and chemical 
stability) as compared to their crystalline counterparts, owing to their thermodynamic 
(higher free energy) and kinetic properties (higher molecular represented by the 
molecular relaxation time constant) [30]. The molecular mobility is usually expressed as 
the polarization time, τ (Tau). The key factor responsible for their physical instability is 
because of their greater molecular mobility.  Several studies have recognized the role of 
molecular mobility in time dependent recrystallization, chemical degradation, and 
structural collapse of amorphous systems.   
The observed molecular mobility is related to chemical reactivity of amorphous 
pharmaceuticals [31-35]. These changes in the pharmaceuticals, may adversely lead to 
altercations in the physicochemical properties and the bioavailability of the molecule 
during storage. Therefore, an acceptable shelf life of amorphous compounds and their 
formulations is of critical importance and this can be determined by reducing the 
molecular mobility. However, a reduction in molecular motions does not necessarily 
result in increased storage stability, because physical characteristics like: dielectric, 
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mechanical and thermal properties may also vary with time and temperature on storage 
[36]. For these reasons, a constant screening for new drug forms including salts is 
ongoing and also because of financial interests caused by legal ramifications [37]. 
Several different techniques i.e., differential scanning Calorimetry (DSC), dielectric 
analysis, isothermal microcalorimetry, mechanical analysis, and solid-state NMR 
spectroscopy have been applied to study the relaxation or polarization phenomena in the 
amorphous pharmaceutical systems. 
The primary aim of this study is to investigate the thermal and electrical behavior 
of pharmaceutical hydrochloride salts including the Lidocaine drug (non-salt) using DEA 
and DSC techniques. This analysis provides a perspective on the use of the data from 
these techniques for predicting the quality, stability and behavior of pharmaceutical salts. 
This study is also aimed at providing a comprehensive characterization of ionic 
conductivity and molecular mobility (related to tan delta in DEA) properties in 
pharmaceutical salts i.e., crystalline and amorphous forms through the measurement of 
the characteristic activation energies and polarization times.  
5.2 Dielectric Analysis (DEA)    
Riga et al. in 2005 published the first study of the physical-chemical properties of 
drugs including drug salts and excipients by dielectric analysis [26]. DEA has come into 
play in the pharmaceutical field because of its unique measurements, the electrical 
properties of the drugs (APIs) or to determine their amorphous and crystalline content. 
DEA measures the ability of dipoles and ions present in a material to align with an 
application of a time dependent alternating electric field as a function of time, 
temperature, and frequency [26 & 29]. The increase in molecular motion associated with 
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the glass transition allows the dipoles or ions in an amorphous material to more freely 
align with the electric field and dissipate energy. DEA measures two fundamental 
characteristics of a material, in our study, of crystalline and amorphous drug salts. First, 
the capacitive nature (permittivity; ε") of the drug salts allows these materials to store 
electric charge. Second, the electrical conductivity (loss factor; ε!) characteristic 
represents the ability of the drug salt to transfer electrical charge or energy to move ions. 
DEA of pharmaceutical drugs, amino acids, organic chemicals, and carbohydrates 
reveals a strong linear conductivity increase prior to the melt, peaking at the melt, 
associated with the dielectric solid-state and viscoelastic properties of the material [26 & 
38].  This DEA technique is a perfect complement to the other different techniques of 
thermal analysis by identifying the phase transitions from the electrical properties of 
materials as a function of time, temperature, and wide range of frequency (e.g. 0.1 Hz to 
100,000 Hz) [39]. The wide frequency range allows measurement of subtle transitions as 
well as multiple-mechanistic transitions that are sensitive to the frequency of 
measurement. Matthews et al. characterized and distinguished the unique dipole 
characteristics of chiral molecules, specifically 20 L-amino acids and 9 D-amino acids by 
employing DEA as an analytical technique. This technique has the capability to explore 
the rheology and molecular mobility of the amino acids 20 to 30 °C below the melting 
temperature established by DSC [40].  
Specific and novel protocols to quantify the crystalline and amorphous content of 
various pharmaceutical drugs by dielectric and calorimetric analysis were developed by 
Maheswaram et al. It was observed that the ionic conductivity of a crystalline drug is 
typically less than   10-1 pS cm-1 at room temperature and a melted drug, an amorphous 
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form, has a conductivity of greater than 105 pS cm-1. Further, the melted drug salts had an 
ionic conductivity of >105 pS cm-1 [29]. The drug salts showed a 10-fold increase in ionic 
conductivity, e.g., Lidocaine hydrochloride conductivity was 106 pS cm-1 and Lidocaine 
(non-salt) 105 pS cm-1. The higher ionic conductivity is an important attribute of a drug 
salt.  
Examination of drug salts by DEA also discovered a strong linear electrical 
conductivity prior to the pre-melt temperature through to the melt. Activation energies 
(Ea, J mol-1) of each drug salt can be calculated from the slope of Arrhenius plots of the 
log conductivity, Ea (k) versus reciprocal temperature in Kelvin [40]. This energy is 
associated with the energy for charging ions in polar materials or relates to the formation 
of charge transfer complexes prior to the melt in the solid state. Second activation energy, 
Ea (τ, Tau) can be calculated via Arrhenius plots of log tan delta peak frequencies vs. 
reciprocal temperature in Kelvin. This Ea (τ) is related to the activation energy for the 
relative rate of change of the ordered charging process, molecular or charge mobility. 
Therefore we can estimate the minimum energy attributed to charging of ions or creating 
charge transfer complexes. Plus, the second Ea (τ) estimates the energy associated with 
molecular mobility.  
The polarization or the response time of the charged ion or ions can be measured 
from a Debye plot, where the inverted peak value is corrected with a constant and 
describes the time for the ions to be polarized for transport in the field. Therefore, DEA 
can be a widely used thermal analytical method that measures polarization response of 
various materials (e.g. drugs, chemicals, carbohydrates, proteins, electro rheological 
fluids etc.) in an AC electric field at isothermal temperatures or by scanning temperature 
94 
techniques [38-44]. The response times were calculated from a Debye plot of tan delta 
(ε!/ ε") vs. log frequency. The response time is directly related to the polarization time, 
which is inversely related to the critical peak frequency in the Debye plot [38]. The 
polarization time is calculated by using the following equation:  
Τ (Tau) = 1/2πfc x 1000 (MS) [see references 38, 45] 
τ (Tau) = Polarization time (millisecond) 
fc = Tan delta critical peak frequency (Hz) 
These analyses demonstrate efforts to correlate the polarization (relaxation) 
properties to the molecular structure and behavior of the material [46].  
5.3 Differential Scanning Calorimetry (DSC) 
DSC is frequently used to measure the physical properties of Active 
Pharmaceutical Ingredients (APIs), and Excipients. This includes melting and 
vaporization temperatures, phase transitions, glass transition, stability, quality and purity 
studies of raw materials and pharmaceutical products. The quality of these 
pharmaceutical materials is based on the melting temperature and peak melting 
temperature, a range of 2 to 3 °C, i.e. melting peak temperature (Tmp) minus the melting 
temperature (Tm).  The heat of fusion of a drug or drug salt is a criterion for drug 
crystalline/amorphous content and its purity. The heat of fusion is usually much greater 
for the salt that melts and decomposes vs. the one that only melts. The DSC curve for the 
former is typically broader at its half maximum, e.g. during decomposition the value is 
17-20 °C and for a pure stable salt the half maximum is 3-5 °C.  The DSC decomposition 
temperature of the drug salt as an exothermic or endothermic process is a key indicator 
that the drug is unstable. The apparent heat of fusion for a pure drug is <300 J/g while the 
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drug salt melting and followed by decomposition, probably endothermically, is 400-500 
J/g. The DSC curve profile is also spiked detected as a second endothermic peak along 
with the melting the first endotherm.  
Careful analysis of the DSC amorphous phase can reveal molecular mobility of 
the pharmaceutical that can be related to its performance.  Amorphous materials have 
varying properties from their crystalline counterparts. Differences in the amorphous 
forms can be related to their kinetic solubility, storage stability as well as their 
mechanical characteristics [47].  These physical amorphous forms lead to unique physical 
chemical attributes and functionalities.  
5. 4 Experimental 
5.4.1 Materials.  The following drug salts were studied by DSC & DEA. 
Procainamide hydrochloride (Tm, 169 °C), Lidocaine (Tm, 68 °C) and Lidocaine 
hydrochloride (Tm, 74–79 °C) were obtained from Sigma-Aldrich (St. Louis, Mo.). 
Fluoxetine hydrochloride (Tm, 156-158 °C) was obtained from Eli Lilly. Hydralazine 
hydrochloride (Tm, 273 °C) was obtained from Alfa Aesar; Quinapril hydrochloride was 
obtained from Toronto Research Chemicals Inc. (Tm, 120-130 °C). 
5.4.2 Uses.  Fluoxetine hydrochloride (Figure 5.1.) is an antidepressant of the 
selective serotonin reuptake inhibitor class. The multiple aromatic rings that are in 
conjugation with the highly electronegative fluorine atoms promote its structural stability. 
Hydralazine hydrochloride (Figure 5.2.) is a smooth muscle relaxant and is an 
antihypertensive. Its potential stability is based on the ring structures but the terminal 
amine is vulnerable and is less stable. Quinapril hydrochloride [48] (Figure 5.3.) is an 
angiotensin-converting enzyme inhibitor (ACE inhibitor) used in the treatment of 
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hypertension and congestive heart failure. Procainamide hydrochloride (Figure 5.4.) is an 
anti-arrhythmic agent used for the treatment of cardiac arrhythmias. Lidocaine 
hydrochloride (Figure 5.5.) is a local analgesic used quite frequently in dentistry and as 
antiarrhythmic drug. Its stability can be based on the ring conjugation with the carbonyl.   
 
Figure 5.1. Skeletal structure of Fluoxetine hydrochloride 
 
 
 
Figure 5.2. Skeletal structure of Hydralazine hydrochloride 
 
 
Figure 5.3. Skeletal structure of Quinapril hydrochloride 
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Figure 5.4. Skeletal structure of Procainamide hydrochloride 
  
 
 
Figure 5.5. Skeletal structure of Lidocaine hydrochloride 
 
5.5 Instrumentation 
5.5.1 Differential scanning calorimetry (DSC). A TAI 2920 DSC was used to 
characterize melting, solid-liquid phase transitions, glass transition temperature (Tg) of 
pharmaceutical hydrochloride salts. Approximately 8-10 mg of sample was mass out and 
placed in sealed aluminum crimped pan (SFI pans) with a pinhole. An empty SFI 
aluminum pan was used as a reference.  A heating rate of 10 °C min-1 was applied to all 
samples. A purge gas of nitrogen was flowed at a rate of 60 mL min-1 during heating and 
cooling cycles. The temperature range was typically from room temperature to 25 to 30 
°C above the melting temperature (Tm) for the salts under study; the glass transition was 
also evaluated and then cooled to room temperature. DSC equipment was preliminarily 
calibrated with standard reference of indium (Tm, 156.6 °C). The purity determination 
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was accomplished with an E698 protocol an ASTM Method. Heat flow (W g-1) values vs. 
time and temperature were generated using Universal Analysis 2000 (TA Thermal 
Advantage) software.  
5.5.2 Dielectric analysis (DEA). A TAI 2970 DEA was used to determine the 
electrical ionic conductivity and Tan delta (ε!/ε") for each drug salt studied. 
Approximately 20 mg of sample was placed on a single surface gold ceramic 
interdigitated electrode (entire electrode was covered). The sample were linearly heated 
at a rate of 10 °C min-1 in a purged inert nitrogen gas flow at rate of 60 mL min-1 from 
room temperature to 25-30 °C above the melting temperature of the salts studied. The 
samples were heated, using the above heating protocol, and air cooled for sequential runs. 
The DEA sensors were calibrated by the TA instrument software, which was initially 
calibrated by a 9-step fixture supplied by TAI. The ionic conductivity (pS cm-1) and tan 
delta measurements were recorded at a controlled interval frequencies ranging from 0.10 
to 10,000 Hz for all the temperatures. These DEA curves were generated using the 
Universal Analysis 2000 software (TA Thermal Advantage software).  
5.6 Results and Discussion 
5.6.1 Dielectric analysis: Ionic Conductivity (pS cm-1).  DEA profiles of the 
drug salts studied show that the initial ionic conductivity for a crystalline drug is 10-2 pS 
cm-1. The ionic conductivity of the amorphous form (liquid) of a non-salt drug (e.g. 
Lidocaine) is 105 pS cm-1. The drug salt in the amorphous form will have an ionic 
conductivity of 106-108 pS cm-1 in the melt. Therefore, the liquid drug salts can be 
modified by electrochemical synthesis in the melt state based on their enhanced ionic 
conductivity. 
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The DEA profile of Fluoxetine.HCl shows the changes in electrical behavior 
associated with solid-solid and solid-liquid transitions. The DEA curve shows a sharp 
linear increase in ionic conductivity leading up to the melt (DSC 157-161oC) in the first 
run and an increase in ionic conductivity with temperature in the second and third runs. 
The ionic conductivity of the Fluoxetine HCl for the crystalline solid at 0.5 Hz (DEA 1st 
run) was 2.18 x 10-3 pS cm-1 at 54.34 o C and at 0.5 Hz it was 55.15 pS cm-1 at 140.60o C.  
In the melt region for DEA run 1 at 0.5 Hz it was 1.12 x 107 pS cm-1 at 164.99o C 
and at 10,000 Hz it was 5.30 x 107 pS cm-1. For the DEA 2nd run the ionic conductivity at 
10,000 Hz was 1.06 x 108 in the melt (164.99o C) and at 0.5 Hz, 139.94o C it was 4.2 x 
105. For the 3rd run at 10,000 Hz, 164.81o C the ionic conductivity was 1.07 x108 pS cm-1 
and at 0.5 Hz, 139.79o C it was 5.13 x 106 pS cm-1 (See Figure 5.6.). The DSC curve for 
Fluoxetine HCl reveals a sharp Tm at 157.45o C and a heat of fusion of 130 J.g-1 (See 
Figure 5.7.). On the cooling cycle it doesn’t recrystallize and therefore it indicates the 
formation of an amorphous material.  
 
Figure 5.6. Log ionic conductivity versus Temperature profile, frequency range of 0.50 Hz – 10,000 Hz, of 
Fluoxetine.HCl; Overlay of DEA 1st, 2nd and 3rd runs 
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Figure 5.7. Fluoxetine.HCl DSC curve showing Tm = 157.45o C, Heat of fusion (130 J g-1) for the first endothermic 
peak 
 
The DSC and DEA profiles of Procainamide.HCl are compiled in Figure 5.8. The 
DSC profile yielded the Tm = 166.63 oC and Tmp (peak melting temperature) = 169.61 o 
C plus the heat of fusion = 104.50 J g-1. The DEA ionic conductivity results are as 
follows: 1st run, 59.80 oC, 0.50 Hz, 4.69 x 10-2 pS cm-1; 152.18 oC, 0.50 Hz, 1.55 x 103 pS 
cm-1; 169.56 oC, 0.50 Hz, 6.63 x 105 pS cm-1. For the 2nd run, at 59.77 oC, 0.50 Hz, 6.44 x 
103 pS cm-1; 152.18o C, 0.50 Hz, 3.36 x 106 pS cm-1; 169.53o C, 0.50 Hz, 1.01 x 108 pS 
cm-1. Consequently, from the crystalline solid (run 1) to the amorphous liquid (run 2) at 
0.50Hz and 152 oC the ionic conductivity increased by 2200 times and at 169 oC it 
increased by 150 times. There is statistical significant difference in ionic conductivity 
from crystalline to amorphous form of the drug salt. Therefore, the first runs of 
Fluoxetine.HCl and Procainamide.HCl are more stable and are of higher quality than the 
higher conducting amorphous second and third runs.  
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Figure 5.8. Overlay of DSC and DEA (1st, 2nd and 3rd runs) profile of Procainamide HCl showing DEA log ionic 
conductivity versus temperature profile, frequency range of 0.50 Hz to 10,000 Hz and DSC profile Tm = 166.6; Tmp = 
169.6o C, Heat of fusion = 104.5 Jg-1 
 
The higher ionic conductivity is an important attribute of a drug salt. The DEA 
ionic conductivity of Lidocaine (non-salt) is 105 pS cm-1 and Lidocaine. HCl is 106 pS 
cm-1 for the amorphous form of the drug salt (2nd run). Clearly the ionic salt (HCl) is 
contributing to the measured higher conductivity, a ten-fold increase. A quality drug salt 
attribute is that the 1st DEA run ionic conductivity is low at room temperature (10-2 pS 
cm-1). As the salt is heated and approaching the melt, in the pre-melt temperature range 
the conductivity increases from ca.10-1 to 106 pS cm-1. Next, in the melt of the drug salt 
the conductivity is >106 to 108 pS cm-1. Further, the DSC profile yields a curve where the 
endothermic melt is a smooth narrow peak with half maxima of 3-5 oC. A drug salt that 
melts and decomposes has a half maxima of >15 oC., e.g. Hydralazine.HCl. Its apparent 
heat of transition, fusion and endothermic decomposition was 300 - 400 J g-1. This 
supports the DEA interpretation of first run (crystalline solid; 104 pS cm-1) ionic 
conductivity decreased on the second run (103 pS cm-1) atypically. 
102 
5.6.2 Activation Energies (J m-1).  It has been observed that some chemicals, 
amino acids and carbohydrates form charge transfer complexes prior to the melt in the 
solid state [29, 40]. A study of the electrical behavior of the drug salts, as determined for 
the amino acids and sugars, yielded repeatable activation energy values which can be 
correlated with real world solid-state properties, e.g. stability and/or quality. Activation 
energies (Ea, J mol-1) of each drug salt either as related to the conductivity (k) or to the tan 
delta (e”/e’) peak frequencies (τ) can be calculated from the slope of Arrhenius plots of 
the log conductivity, Ea (k) or Ea (τ) versus 1/ temperature (K) x 1000. Therefore we can 
estimate the minimum energy attributed to charging of ions or creating charge transfer 
complexes and the energy associated with molecular or charge mobility. 
The Activation energies Ea (k) (J m-1) for the drug salts were evaluated at 0.50 Hz 
and at a temperature range of 20 oC to 30 oC below the DSC peak melting temperature 
employing an Arrhenius plot (See Table 1). The Ea (k) for Fluoxetine HCl (See Figure 
5.9.), Procainamide HCl (See Figure 5.10.), and Quinapril HCl (See Figure 5.11.) were 
calculated from the DEA plots of Ionic conductivity (pS cm-1) vs. temperature. DEA 1st 
run (Crystalline Solid); DEA 2nd run (Amorphous), and 3rd run (Amorphous) Ea (k) 
values for all the drug salts studied are summarized in Table 1. 
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Table 1  
Activation Energies Ea (k) of Drug Salts 
Activation Energies: Ea (k) J m-1 
Drug Salts 
DEA 1st Run DEA 2nd Run DEA 3rd Run 
Crystalline Amorphous Amorphous 
Procainamide.HCl 501 81 83 
Fluoxetine.HCl 956 227 35 
Lidocaine.HCl 340 33 31 
Quinapril. HCl 380 176 134 
 
 
Figure 5.9. Overlay of DEA (1st, 2nd and 3rd runs) log ionic conductivity versus temperature profile of Fluoxetine 
HCl at 0.50 Hz 
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Figure 5.11. Overlay of DEA (1st, 2nd and 3rd runs) log ionic conductivity versus temperature profile of Quinapril 
HCl at 0.50 Hz 
The Ea (k) for the 4 crystalline drug salts studied (DEA 1st run) was 340-956 Jm-1. 
The Ea (k) for the 2nd and 3rd runs of Procainamide.HCl (501 J m-1) and Lidocaine.HCl 
Figure 5.10. Overlay of DSC and DEA (1st, 2nd and 3rd runs) profile of Procainamide HCl showing DEA log ionic 
conductivity versus temperature profile at 0.50 Hz and DSC profile Tm = 166.6; Tmp = 169.6o C, Heat of fusion = 
104.50 J g-1 
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(340 J m-1) decreased from a higher value to a constant lower value of 82 and 32 J m-1, 
respectively.  Fluoxetine.HCl and Quinapril.HCl decreased by 85% and 24% of the 1st 
run Ea (k) value, respectively. A curve fit of the log conductivity vs. 1/T (K) x 1000 
produced a linear curve with a correlation coefficient of R2 = 0.996 or greater for all the 
drug salts (see Figure 5.12. for Fluoxetine.HCl Arrhenius plots). The Ea (k) is used to 
rank crystallinity/amorphicity in pharmaceutical solids [29], that is, a high Ea (k) value is 
crystalline material and low Ea (k) value is amorphous material. An Ea (k) value of <140 
J m-1 suggests that the material is amorphous.  
 
 
Figure 5.12. Arrhenius plots of Fluoxetine.HCl (1st, 2nd, 3rd runs; 0.5Hz); Ea = 956, 227, 35 J m-1 respectively 
 
5.6.3 Tan delta.  The Activation energies Ea (τ) for the drug salts were evaluated 
as a function of frequency and temperature. An Arrhenius plot was used to determine the 
Ea (τ) for each drug salt i.e. crystalline or amorphous material. The log tan delta peak 
frequencies (Hz) vs. reciprocal temperature in Kelvin x 1000 for the drug salts studied is 
summarized in Table 2. Tan delta curves for all the drug salts revealed a weak spectrum 
in the first run of the crystalline solid (Figure 5.13.). The second and the third runs 
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revealed strong spectra (See Figure 5.14. and 5.15. respectively). The resulting Ea (τ) 
only yields values after the 2nd and 3rd DEA scanning runs, as the material is amorphous. 
The Ea (τ) from run 2 to run 3 was constant for Procainamide.HCL at 84 J m-1 (See 
Figure 5.16.), Fluoxetine.HCl at 78 J m-1 and Quinapril.HCl at 25 J m-1. The constant Ea 
(τ) values in the amorphous phase indicate the presence of a stable material. For 
Lidocaine.HCl, the Ea (τ) varied from the 2nd run (148 J m-1) to the 3rd run ending in (20 J 
m-1). This can be interpreted that there is some variability in this salt possibly related to 
the hydroscopic nature of this compound. The water aggregating on the salt can cause the 
variation in its solid – liquid state properties.  This analysis scheme can be developed to 
predict storage stability or shelf life with a detailed experimental analysis based on the Ea 
(τ). 
Table 2  
Activation Energies Ea (τ) of Drug Salts 
Activation Energies : Ea (τ) J m-1 
Drug Salts 
DEA 1st Run DEA 2nd Run DEA 3rd Run 
Crystalline Amorphous Amorphous 
Procainamide.HCl Not Observed 84 85 
Fluoxetine.HCl Not Observed 78 79 
Lidocaine.HCl Not Observed 148 20 
Quinapril.HCl Not Observed 25 25 
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Figure 5.13. Tan Delta versus log frequency profile of Fluoxetine.HCl (DEA 1st run) 
 
 
Figure 5.14. Tan Delta versus log frequency profile of Fluoxetine.HCl (DEA 2nd run) 
 
108 
 
Figure 5.15. Tan Delta versus log frequency profile of Fluoxetine.HCl (DEA 3rd run) 
 
 
Figure 5.16. Overlay of Tan Delta versus log frequency profile of Procainamide.HCl (DEA 1st and 3rd runs) 
5.6.4 Polarization times (ms).  The polarization times for these drug salts were 
calculated from a Debye plot of tan delta (ε!/ ε") vs. log frequency. These analyses 
demonstrate efforts to correlate the polarization (relaxation) properties to the molecular 
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structure and physical as well as electrical behavior. The polarization or response time to 
the AC electrical field produces a peak value where the loss factor is equal to the 
permittivity (ε!= ε") and the molecular mobility is enhanced. This enhanced molecular 
mobility behavior of the amorphous materials is thought to be the cause of their 
significant tendency towards crystallization, structural collapse, and chemical 
degradation. Studying the polarization times and the accompanying activation energy Ea 
(τ) gives us the opportunity to determine the effect of environment on the molecular 
mobility of the drug salts. We can also predict the storage stability or desirable shelf life 
of crystalline/amorphous pharmaceutical systems.  
The polarization time for Fluoxetine.HCl DEA 1st run (crystalline solid) was 690 
milliseconds. For Lidocaine.HCl and Procainamide.HCl the τ was 530 milliseconds 
indicating longer polarization times reflecting a stable material. The 2nd and 3rd DEA runs 
of the amorphous form of the drug salts exhibited a distribution of polarization times due 
to the dynamically heterogeneous nature of the amorphous state. However, a crystalline 
Quinapril.HCl after the first DEA run produced a τ of 0.320 milliseconds, shorter times 
for a crystalline drug salt is indicative of enhanced molecular mobility behavior. This 
change suggests a structural collapse or chemical degradation as the crystalline material 
becomes amorphous.  
5.7 Conclusions  
In the development of the solid pharmaceutical forms, quality control, stability 
and behavior of the materials are important parameters to ensure the final product quality. 
This study aids in the selection and evaluating the drug salt candidates by DEA and DSC 
techniques. Salts with advantageous properties are typically patentable as new chemical 
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entities. The relative amount crystalline/amorphous content in pharmaceutical solids can 
be clearly identified by DEA activation energy, Ea (k) [29]. The higher conductivity of 
the salt promotes better solubility and bioavailability characteristics. Evaluation of drugs 
by DEA yields to a more conducting amorphous phase with the HCl salt e.g. 
Lidocaine.HCl (106 pS cm-1) and Lidocaine (105 pS cm-1). The DSC melting profile of 
the salt form of Lidocaine (i.e. Lidocaine.HCl) had a higher melting temperature or a 
more stable phase. The first DEA run of the drug salts are more stable and of higher 
quality than the higher conducting amorphous 2nd and 3rd runs. A combination of DEA 
and DSC profiles can identify a vulnerable drug salt through decomposition (e.g. 
Hydralazine.HCl).  
The identification of the pre-melt and melt ionic conductivities and activation 
energies for the drug salts appears to be a pathway for establishing the experimental 
conditions that can be used to modify the quality, stability and performance of the final 
drug product. We can predict the minimum activation energy Ea (k) attributed to 
charging ions or creating charge transfer complexes and activation energy Ea (τ) 
associated with charge mobility. The DEA properties described here can be further 
developed to estimate the storage stability or shelf life of the drug salts by Ea (τ) and 
polarization times. Stable drug salts by DEA evaluation renders an Ea (τ) that is constant 
in the 2nd to the 3rd DEA runs. The approaching stability of the amorphous phase relates 
that the Ea (τ) remains constant, as observed for Lidocaine HCl.  
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CHAPTER VI 
DIELECTRIC PROPERTIES OF PHARMACEUTICAL SOLIDS REVEAL 
UNIQUE AMORPHOUS CHARACTERISTICS: VALIDATED BY THERMAL, 
MICROSCOPIC AND X-RAY METHODS 
6.1 Introduction 
 Diffraction techniques are the most defined methods for detecting and 
quantifying the crystalline and amorphous content in any pharmaceutical system. For 
example, Powder X-ray Diffraction Analysis (PXRD) of APIs and excipients gives a 
good observation of the crystalline phase. The diffraction planes of the given sample 
delineate the interplanar distances that identify the crystalline character. The area under 
the diffraction peaks, either a key intense peak or series of peaks, can be related to the % 
crystallinity. The amorphous content in this analysis is then measured by difference from 
100% crystalline. Alternately, the amorphous phase is only seen as broad diffuse XRD 
bands. The area under the amorphous bands has been correlated to the amorphicity, but 
with a great deal of specific requirements per XRD pattern. Although, these methods only 
“observe” the molecular order, and the disorder in the system is predicted by the absence 
of the order [1].  Complications and errors in interpretation arise due to complex 
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scattering patterns of the sample, weak diffraction peaks, preferred crystal orientation, 
and optimized particle size so as not to contribute to line intensity broadening, and finally 
instrumental errors. The main disadvantage in using this approach is that it cannot 
differentiate surface/ bulk amorphicity. 
       Additional analytical techniques used to characterize amorphous pharmaceutical 
solids with thermal energy as the basic principle are DSC, IMC, and SC. DSC is the most 
relevant and significant method that is used to characterize the melting behavior, purity, 
glass transitions, crystallization, polymorphism, solid-solid transitions and chemical 
reactions of the drug including the detection of the amorphous content [2, 3]. DSC is 
performed by heating the sample through its melting point with linear heating rate of 2.0 
to 10 oC min-1. As Tg is the characteristic property of amorphous material, the DSC scan 
of an amorphous or blend of crystalline/ amorphous material shows a glass transition, 
with crystallization exothermic peak, and melting endothermic peak [1, 2, 4]. Amorphous 
content is quantified in a sample by preparing a calibration curve using 100% amorphous 
and crystalline standards and their blends, and with their respective heats of fusion (∆Hf) 
and crystallization [2].  
Using, XC (%) = (∆H/∆Ho)*100         [1, 2, 4] 
Where, ∆His the Heat of fusion of the sample and ∆Ho is that of the 100% crystalline 
standard. Also, amorphous content can be calculated without the calibration curve using 
the equation: 
Amorphous content = ∆Hf amorphous /∆Hf crystalline 
Where, ∆Hf amorphous is heat of fusion of amorphous portion and ∆Hf crystalline is 
the heat of fusion for the pure crystalline material.  
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       Although proven, DSC technique shows several drawbacks: that it cannot 
differentiate surface vs. bulk amorphicity; thermal changes in the sample during the scan 
or given time after the scan; crystallinity is measured during the melting process. The key 
parameter for identifying the amorphous phase is the glass transition temperature. 
However, the amorphous content is only qualitatively related to the Tg and not 
quantitatively proportional to it. In order to obtain reliable results several variables like 
sample size, sample pan used (open or closed), and the thermal contact resistance 
between the sample pan and the DSC cell has to be considered. 
    It is well known that DSC melt properties are correlated to the structure of the 
drug, which can be validated by a variety of structural tools like PXRD [2, 5] and 
Scanning Electron Microscopy (SEM) [2]. Morphological and thermodynamic transitions 
in drugs as well as their amorphous and crystalline content in the solid state have been 
initiated by thermal analytical techniques, which include Dielectric Analysis [3, 5]. 
The primary aim of this study is to achieve the amorphization of the APIs 
Clopidogrel hydrogen sulfate [6] and Quinapril.HCl [7] by solvent evaporation method. 
A further aim is to characterize the crystalline and amorphous content in these APIs by 
the DEA activation energy method. Finally, the dielectric science developed to 
understand the crystalline and amorphous components in pharmaceuticals would be 
validated by Calorimetry, X-ray diffraction and scanning electron microscopy.  
6.2 Materials and Experimental Procedure  
6.2.1 Materials. The following drugs were evaluated in this study: Lidocaine.HCl 
(Tm, 74°-79°C), Sulfapyridine (Tm, 192°C), Indomethacin (Tm, 155°C), Quetiapine 
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fumarate (Seroquel®) (Tm, 173°C), Procainamide.HCL (Tm, 169°C), Clopidogrel 
hydrogen sulfate (Tm, 177.4 °C), Quinapril.HCl (Tm, 120-130 °C). 
6.2.2 Preparation of amorphous form of a drug   
  6.2.2.1Clopidogrel Hydrogen sulfate (CHS).  Amorphous samples were made 
using ethanol. 100 mg of CHS was dissolved in sufficient amount of ethanol with 
magnetic stirrer for 5 min at room temperature [6]. The solvent was evaporated by two 
methods: with blown room temperature air or by vacuum. After drying, samples were 
pulverized in a porcelain mortar with a pestle. DEA, DSC, PXRD and SEM techniques 
were used to characterize the amorphous and crystalline forms of Clopidogrel hydrogen 
sulfate. 
6.2.2.2 Quinapril.HCl (Q.HCl). Q.HCl was dissolved in a minimum amount of 
dichloromethane required to form a solution [7]. The solvent was removed initially using 
a rotary evaporator under vacuum at room 30o C, and the residue was dried under vacuum 
for 24 hrs. DEA, DSC, PXRD and SEM techniques were used to characterize the 
amorphous and crystalline forms of Q.HCl. 
6.2.3 Experimental procedure. 
6.2.3.1 Differential scanning calorimetry.  DSC studies were performed with a 
TAI 2920 DSC instrument with samples of   approximately 5-10 mg weighed into non-
hermetically sealed pans. The samples were heated from room temperature to 20 oC 
above the peak melting temperature at a heating rate of 10 oC/min. The instrument was 
calibrated with use of indium.  
6.2.3.2 Dielectric analysis.  A TAI 2970 DEA (TA Instrument) was used to 
determine the electrical conductivity for each drug studied. Sample of approximately 20 
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mg was placed on a single surface gold ceramic interdigitated sensor. The samples were 
ramped at a rate of 10 oC min-1 from room temperature to 20 oC above the melting 
temperature of the drug. The conductivity measurements were recorded at controlled 
interval frequencies ranging from 0.10 to 10,000 Hz for all temperatures. 
6.2.3.3 X-ray powder diffraction (PXRD).   XRD patterns were obtained using an 
X’Pert PRO MPD system (X-ray Diffractometer Phillips). Where the tube anode was Cu 
with Kα1= 1.5408 Å. The pattern was collected at a tube voltage of 45kV and a tube 
current of 35 mA in step can mode. Angle range: 10o to 80o 2Θ.  The data were evaluated 
with origin software or JADE software. The powder diffraction files come from the 
International Center for Diffraction Data (ICDD). 
6.2.3.4 Scanning electron microscopy. The surface morphology of various 
amorphous drug samples was investigated using an Amray 1830 scanning electron 
microscope. The dry powder was mounted onto metal stubs by applying silver paint onto 
the metal stubs. The drug sample was sprinkled on the silver paint and then it is dried. 
Then the samples are vacuum-coated with a platinum film using a gold sputter coater 
unit.  
6.3 Results and Discussion  
We tested the applicability of the novel activation energy method for quantifying 
crystalline and amorphous content with several other pharmaceutical solids including the 
amorphous forms of the API prepared by solvent evaporation methods e.g., Clopidogrel 
hydrogen sulfate and Quinapril.HCl. The DEA results obtained from the activation 
energy method for all the drugs studied were validated with other established methods, 
e.g., DSC, PXRD and SEM analysis.  
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6.3.1 DEA study.  The comparison of four runs of Clopidogrel hydrogen sulfate 
by DEA and DSC are overlayed in Figure 6.1. The ionic conductivity in crystalline and 
amorphous samples as a function of temperature were used to calculate the activation 
energy from 0.1-10,000 Hz (first and second runs) [8, 9]; Clopidogrel HS pure 
amorphous sample DEA run overlays the DEA amorphous run 2; DSC Tm = 176.11oC, 
Tmp = 179.42 oC, Heat of fusion = 81.33 J/g. Therefore, the DEA 2nd run was the same 
as the 1st run prepared out of the DEA i.e., the sample prepared with ethanol by solvent 
evaporation method, was amorphous. To confirm that the prepared sample was 
amorphous, a DSC analysis was performed (See Figure 6.2). The characteristic melting 
point disappeared completely from the DSC curve; a Tg [10] was observed. The resulting 
Tg was at 89 oC and the ΔCp at Tg was 0.256 J/g/C. The result confirms the presence of 
the amorphous form by DEA and DSC.  
Figure 6.3. shows the DEA surface analysis profile for Clopidogrel hydrogen sulfate at 
0.1 Hz.  
 
Figure 6.1. DEA and DSC curve overlay of Clopidogrel hydrogen sulfate. DEA 1st run Crystalline (Green) and 2nd 
run Amorphous (Blue); DEA 1st run pure amorphous form (Prepared  (Brown) 
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Figure 6.2. Glass transition temperature of Clopidogrel hydrogen sulfate measured by DSC; Tg = 89.32o C 
 
 
 
Figure 6.3. Clopidogrel hydrogen sulfate DEA curve overlay of crystalline and amorphous sample by activation energy 
method surface analysis at 0.1 Hz (first and second runs) 
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Table 1 identifies the activation energies for Clopidogrel hydrogen sulfate (Ea in J/mol) 
with the higher value for the crystalline form (DEA 1st run) and a significantly lower 
value for the amorphous form (DEA 2nd run). For the 2nd run at 0.1, 0.5, and 1.0 Hz the 
amorphous sample content was 76-78% (See Table 2).  
Table 1  
Clopidogrel hydrogen sulfate DEA activation energy (J/mol), % crystalline, and % 
amorphous content for first and second runs at 0.1, 0.5, and 1 Hz frequencies  
Clopidogrel 
hydrogen 
sulfate 
Frequency/ 
Hz 
DEA 
Run 
Ea/ 
Jmol-1 
% Crystalline 
content 
% Amorphous 
content 
Crystalline  0.1 1 622 100 0 
Amorphous  0.1 2 138 22 78 
Crystalline  0.5 1 576 100 0 
Amorphous  0.5 2 136 24 76 
Crystalline  1 1 576 100 0 
Amorphous  1 2 138 24 76 
 
Table 2 summarizes Clopidogrel hydrogen sulfate DEA activation energies for the pure 
crystalline form and the pure amorphous form, for Run1 at 0.1, 0.5 and 1.0 Hz. 
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Table 2  
Clopidogrel hydrogen sulfate DEA activation energy (J/ mol), % Crystalline, and % 
amorphous content for first run crystalline sample and first run pure amorphous sample  
Clopidogrel 
hydrogen sulfate 
Freq/ 
Hz 
Run Ea/ J mol-1 
% Crystalline 
Content 
% Amorphous  
Content  
Crystalline 0.1 1 622 100 0 
Amorphous 
(Pure) 
0.1 1 138 22 78 
Crystalline 0.5 1 576 100 0 
Amorphous 
(Pure) 
0.5 1 130 23 77 
Crystalline 1 1 576 100 0 
Amorphous 
(pure) 
1 1 127 22 78 
 
Quantification of crystalline and amorphous drug content of Clopidogrel 
hydrogen sulfate by DEA activation energy method is summarized in Table 3. The 
activation energies for the DEA amorphous form of the drug (2nd run) correlate with 
activation energies for the pure amorphous form prepared with ethanol (1st run). The 
average content of the DEA 1st run for the pure amorphous form prepared with ethanol 
was 22% crystalline and 78% amorphous (0.1- 1.0 Hz). For the 2nd run of DEA 
amorphous form the average content was 23% crystalline and 77% amorphous (0.1-
1.0Hz). 
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Table 3  
Quantification of crystalline and amorphous drug content of Clopidogrel hydrogen sulfate 
by DEA activation energy method  
Drug 
Average content of DEA first run (pure Amorphous Form) 
at 0.1, 0.5, and 1.0 Hz 
% Crystalline content % Amorphous content 
Clopidogrel 
hydrogen sulfate 
22 78 
 
The summary table 4 describes the average value of the content, both % crystalline and 
amorphous, for the drugs studied by DEA activation energy method, at various 
frequencies for the 2nd and 3rd DEA runs. 
Table 4 
Quantification of crystalline and amorphous drug content of various pharmaceutical APIs 
by the DEA activation energy method 
Drugs 
Average content of second and third DEA runs  
at 0.1, 0.5, and 1.0 Hz 
 % Crystalline content  % Amorphous content 
Clopidogrel hydrogen sulfate  23 77 
Quinapril HCl 35 65 
Quetiapine Fumarate  11 89 
Lidocaine.HCl 22 78 
Sulfapyridine 19 81 
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6.3.2 DSC study.  A well-established tool for pharmaceutical analysis is DSC, 
which can examine the degree of fusion and crystallization of an API. The heat of fusion 
(J/g) associated with the first DSC examination of the crystalline API (run 1) is recorded. 
The thermal analysis curve represents a physical chemical property of the sample drug, 
i.e., melting. Cooling of the API sample after melting through the crystallization yields 
the temperature and heat of crystallization (J/g). This cooling DSC data is a measure of 
the amount of sample recrystallized.   
The ratio of the heat of crystallization divided by the heat of fusion times 100 is 
the % crystalline and the difference is the % amorphous content. For example, 
Sulfapyridine melts at a 192 oC (run 1) and crystallized at 123 oC (run 2) in the DSC 
Cooling cycle. The measured heat of fusion was 174 J/g and heat of crystallization was 
57 J/g, see Figure 6.4. Therefore the recrystallized sample contained 33% crystalline and 
67% amorphous material. The % amorphous by DEA activation method is 81% and by 
this DSC heat-cool method is 67% amorphous.  The other drugs analyzed by the DSC 
heating and cooling cycles are listed in the Table 5. 
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Figure 6.4. DSC curve of Sulfapyridine showing Heat-Cool cycle; Tm = 191oC, Tmp =194.39o C, Heat of Fusion = 
174 J/g; Heat of Crystallization = 57 J/g, Tmc=119oC, Tmpc = 123o C 
 
6.3.2.1 Confirmation of amorphous form by DSC.  Prepared amorphous sample 
i.e., Clopidogrel hydrogen sulfate amorphous was measured primarily by DSC. 
Characterization of amorphous form by DSC is quick and easy. The pure crystalline 
forms of both the drugs were tested at first by DSC (see Figure 6.1). The crystalline 
Clopidogrel hydrogen sulfate melted at 176.11o C.  The Heat of Fusion was 81.33 J/g. 
The samples prepared in ethanol, dried in vacuum were transformed to the amorphous 
form. The characteristic melting point disappeared completely from the DSC curves of 
the amorphous form. The glass transition temperature is a very important parameter for 
amorphous materials. Approximately for the all the amorphous materials the Tg is 
usually observed at 2/3 to 4/5 of Tm (in Kelvin) [6]. The melting point of crystalline 
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Clopidogrel hydrogen sulfate is 176.11oC (449.11 K). Accordingly, the expected Tg for 
Clopidogrel hydrogen sulfate is the temperature interval of 26.4 - 86.2 oC.  
The DSC curve reveals all the structural changes accompanied by enthalpy 
changes. The Tg is usually indicated by a step in the DSC curve. However, for the first 
heat cycle of Clopidogrel hydrogen sulfate Tg could not be detected. The Tg was 
observed or appeared in the 2nd heating curve of DSC (see Figure 6.2). The resulting Tg 
was at 89o C and the ΔCp at Tg was 0.256 J/g/C.   
Quinapril.HCl amorphous sample was prepared by solvent evaporation method. 
The solvent used to prepare the amorphous sample was dichloromethane. DSC was used 
to determine the physical properties i.e., the glass transition temperature. For the 
amorphous Quinapril.HCl the Tg was observed at 79 – 85 oC for the first and the second 
heating cycle respectively. The melting point of crystalline Quinapril.HCl was 104 oC 
and Heat of fusion = 25J/g. The other drugs analyzed by the DSC heating and cooling 
cycles are listed in the Table 5. 
  Table 5 
Summary of DSC heat-cool method for all the drugs studied 
Drugs Tm oC 
Heat of Fusion 
ΔHf (J/g) 
Heat of crystallization 
ΔHc (J/g) 
% Crystalline % Amorphous Comments 
Lidocaine.HCl 79 201 Tg = 17oC - - Amorphous 
Sulfapyridine 192 174 57, Tg = 61-62oC 33 67 
Semicrystalline 
&Amorphous 
(2nd Heat Cycle) 
Quetiapine Fumarate 173 124 Tg = 44-49oC - - Amorphous 
Indomethacin 155 127 Tg = 42-47 oC - - Amorphous 
Quinapril.HCl 104 25 
1st run Tg = 79 oC & 
2nd run Tg = 85oC 
- - Amorphous 
Clopidogrel hydrogen sulfate 179 81 
2nd Heating 
Tg = 89 oC 
- - Amorphous 
Procainamide.HCl 169 83 Tg = 47 oC - - Amorphous 
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6.3.3 Powder x-ray diffraction (PXRD) analysis. 
6.3.3.1 Methodology. X-ray Diffraction Analysis (XRD) is a structural tool to 
identify APIs based on their molecular structure. Each drug has its own unique crystal 
structure. If single crystal diffraction data is appropriately available the exact space group 
structure can be determined clearly distinguishing it from most other structures. The 
complex structure of pure drugs yields to an API crystal system probably an 
orthorhombic, monoclinic or triclinic system. Most drugs analyzed by Wide Angle XRD 
(WAXRD) can be viewed as multiple sharp intense peaks (half peak maxima typically 
0.3o 2Θ) delineating their highly crystallinity nature. Contrary to the multiple sharp peaks 
are the broad XRD bands (half maxima of 5-10o 2Θ) typical of amorphous materials. 
Therefore, a sharp peak spectrum is a crystalline material and a broad diffuse peak 
spectrum is an amorphous material.  
All drugs examined by PXRD were first evaluated by DEA and then sampled for 
PXRD.  
6.3.3.2 Confirmation of Clopidogrel hydrogen sulfate and Quinapril.HCl 
amorphous form by PXRD.  The Clopidogrel hydrogen sulfate (CHS) and Quinapril.HCl 
(Q.HCl) amorphous samples were tested by PXRD measurement. Diffractograms are can 
be seen in (Figure 6.5) and (Figure 6.6) respectively. The investigation supported the 
DSC results throughout for both Clopidogrel hydrogen sulfate and Quinapril.HCl. Figure 
6.5 shows that the products prepared with ethanol for Clopidogrel hydrogen sulfate and 
dichloromethane for Quinapril.HCl (see Figure 6.6) were converted to the amorphous 
form, because the peaks disappeared from the diffractograms, and the spectra became 
smooth. The DSC and the PXRD results suggested that samples prepared by solvent 
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evaporation method for both the crystalline drugs i.e., CHS and Q.HCl were transformed 
to the amorphous form. 
 
 
Figure 6.5. Clopidogrel hydrogen sulfate samples measured by PXRD. (A) Crystalline form, (B) Amorphous sample 
prepared with ethanol, dried under vacuum, (C) ICDD diffractogram of Clopidogrel hydrogen sulfate (bottom curve) 
 
Figure 6.6. PXRD diffractograms of different batches of Quinapril.HCl amorphous forms. Amorphous samples 
prepared with dichloromethane, dried under vacuum 
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Indomethacin was initially crystalline and after either quench cooling or heating it 
in the DEA and cooling to room temperature became amorphous. This behavior was also 
observed in the diffractogram of the amorphous Indomethacin with broad diffuse XRD 
bands. The diffractograms of pure crystalline and amorphous forms of Indomethacin is 
shown in Figure 6.7. The indomethacin diffractogram shows that the sample that was 
heated in the DEA was amorphous, because the peaks disappeared from the 
diffractograms of the amorphous Indomethacin sample, and the spectra became smooth.  
Likewise, Lidocaine.HCl, Quetiapine fumarate, Sulfapyridine (Figure 6.8), Quinapril.HCl 
and Clopidogrel hydrogen sulfate all became totally amorphous after the DEA first run. 
Also, PXRD analysis aided the determination of the amorphous/crystalline form whether 
it was a surface vs. bulk identification by DEA activation energy method.  
 
Figure 6.7. PXRD diffractograms of Indomethacin Crystalline and Amorphous forms. Amorphous sample analyzed on 
DEA, Bottom curve (ICDD) 
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Figure 6. 8. PXRD of Sulfapyridine Crystalline Form and DEA amorphous form, bottom curve (ICDD) 
 
The summary of all the drugs, their identity (ICDD), distribution of crystalline peaks and 
amorphous bands is elucidated in Table 6. 
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Table 6 
Summary of all the drugs, their identity (ICDD), distribution of crystalline peaks and 
amorphous bands 
PXRD Peak Values 2 Θ / Cu Kα Radiation 
Drugs 
Identity 
ICDD 
Crystalline Peaks Amorphous Bands 
Lidocaine.HCl Yes 10 12 15 
16, 21, 
25, 27 
17 25 37 50 
Sulfapyridine Yes 11 12 15 
16, 20, 
22,23,24,
25, 28 
16 21 28 45 
Quetiapine Fumarate 
(Seroquel) ® 
Yes 15 16 20 
21, 22, 
23, 25 
16 22  45 
Procainamide. HCl Yes 16 17 19 
21, 24, 
26, 29, 
30 
 28  46 
Clopidogrel 
hydrogen sulfate 
Yes 13 15 18 
19, 21, 
23, 24, 
25 
19 26 45 57 
Quinapril.HCl 
(Accupril)® 
Yes 8 12 14 
18, 22, 
23, 25 
18   58 
Indomethacin Yes 11 17 20 
22, 27, 
29, 31 
 22 29 50 
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6.3.4 Scanning electron microscopy study. 
6.3.4.1 Clopidogrel Hydrogen Sulfate. SEM photomicrographs obtained for a 
pure crystalline form of Clopidogrel Hydrogen Sulfate (CHS) and an amorphous form of 
CHS are shown in (Figure 6.9 and Figure 6.10) in selected magnifications. From the 
photomicrograph of pure drug CHS; it is clear that the drug was present as irregularly 
shaped beads and aggregate structures confirming the crystal nature of the material as 
seen by DEA, DSC, PXRD data analyses.  
 
Figure 6.9. SEM photomicrographs of pure crystalline drug Clopidogrel Hydrogen Sulfate  at (a) 75X (top left); (b) 
300X (top right) and (c) 1080X (bottom); 15 KV 
 
The CHS amorphous form by SEM was identified as a flexible soft structure and 
as layered plates or a round structure as soft scales (see Figure 6.10). The DSC and DEA 
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as well as PXRD analysis of the CHS amorphous material correlates with the SEM 
images.  
 
Figure 6.10. SEM photomicrographs of amorphous forms of Clopidogrel Hydrogen Sulfate at (a) 89X (top left); (b) 
102X (top right) and (c) 161X (bottom); 15 KV 
 
6.3.4.2 Quinapril.HCl . SEM photomicrographs obtained for pure crystalline 
forms of Quinapril.HCl (Q.HCl) and an amorphous form of Q.HCl are shown in (Figure 
6.11 and Figure 6.12) in selected magnifications. From the photomicrographs of pure 
drug Q.HCl; it is clear that the drug was present as a rod-like structure (1260X), 
overlayed rods (200X) and an aggregate like structure at 100X. SEM photomicrographs 
of the amorphous forms of Quinapril.HCl are viewed in Figure 6.12. The droplet-like 
structures were apparently amorphous and underwent fluid flow.  
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Figure 6.11. SEM photomicrographs of pure crystalline drug Quinapril.HCl at (a) 1260X (top left); (b) 200X (top 
right) and (c) 100X (bottom); 15 KV 
 
Figure 6.12. SEM photomicrographs of amorphous forms Quinapril.HCl at (a) 160X  (top left); (b) 304X (top right) 
and (c) 565X (bottom); 15 KV 
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6.3.4.4 Quetiapine fumarate (Seroquel). SEM photomicrographs obtained for 
pure crystalline form of Quetiapine Fumarate (Seroquel) and an amorphous form of 
Quetiapine Fumarate (Seroquel) are shown in (Figure 6.13 and Figure 6.14) at selected 
magnifications. From the photomicrographs of pure crystalline drug we can clearly 
differentiate the amorphous form of the drug, where the structures are smooth, and no 
distinct edges as well as appeared to have smooth surfaces.  
 
Figure 6.13.  SEM photomicrographs of pure crystalline drug Quetiapine Fumarate (Seroquel) at (a) 342X (top left); 
(b) 915X (top right) and (c) 1100X (bottom); 10 KV 
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Figure 6.14. SEM photomicrographs of amorphous form Quetiapine Fumarate (Seroquel) at (a) 25X (top left); (b) 50X 
(top right) and (c) 70X (bottom); 10 KV 
 
6.3.4.4 Sulfapyridine.  SEM photomicrographs obtained for pure crystalline form 
of Sulfapyridine and an amorphous form of Sulfapyridine are shown in (Figure 6.15) in 
selected magnifications. From the photomicrograph of pure drug sulfapyridine it was 
present as triangular crystals and the amorphous form was a block of the material with 
surface fragments.  
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Figure 6.15. SEM photomicrographs of pure crystalline drug Sulfapyridine and amorphous drug Sulfapyridine (a) 
165X (Left, Crystalline Solid); (b) 304X (Right, Amorphous); 15 KV 
 
6.3.4.5. Lidocaine.HCl.  SEM photomicrographs obtained for pure crystalline 
forms of Lidocaine.HCl are shown in (Figure 6.16) in selected magnifications. From the 
photomicrograph of pure drug Lidocaine.HCl it is clear that the drug had geometric 
shapes as plates and rods. The amorphous form of this drug was hygroscopic resulting in 
a rubbery sticky structure. This was not amenable for SEM analysis. This amorphous 
compound was analyzed by DEA. 
 
Figure 6.16. SEM photomicrographs of pure crystalline Lidocaine.HCl (a) 100X (Left);  (b) 200X (Right); 10 KV 
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6.4 Conclusions 
We were successful in establishing new DEA analytical methods to determine the 
crystalline and amorphous content of drugs. i.e., the two DEA methods, the activation 
energy method, as well as, the empirical method agreed with a correlation coefficient of 
0.96. This protocol was additionally validated by DSC studies. DSC Analysis verified the 
presence of amorphous and crystalline material based on changes in the heat of fusion 
and the appearance of an amorphous Tg. PXRD succinctly separated the amorphous and 
crystalline materials based on the multiple sharp and narrow peaks for crystalline 
materials and exceptionally broad bands for the amorphous materials. SEM analysis 
revealed softening and rounding on edges of amorphous materials while not changing 
those images of crystalline structure. 
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